

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: G01N 33/96, 33/68	A1	(11) International Publication Number: WO 97/27486 (43) International Publication Date: 31 July 1997 (31.07.97)
(21) International Application Number: PCT/US97/01074 (22) International Filing Date: 17 January 1997 (17.01.97) (30) Priority Data: 08/589,939 23 January 1996 (23.01.96) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: HACKETT, John, R., Jr.; 917 Vose Drive #211, Gurnee, IL 60031 (US). HOFF, Jane, A.; 313 E. 12th Avenue, Naperville, IL 60563 (US). OSTROW, David, H.; 985 Manchester Court, Lake Zurich, IL 60047 (US). GOLDEN, Alan, M.; 2516 Laurel Lane, Wilmette, IL 60091 (US). (74) Agents: BECKER, Cheryl, L. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: REAGENTS FOR USE AS CALIBRATORS AND CONTROLS (57) Abstract The present invention relates to the use of a reagent that binds specifically to a predetermined ligand, contains one or more antibody constant region epitopes, and is uniform in specificity and affinity. The reagent can be produced continually, in the manufacture of calibrators (standards) and/or controls for diagnostic kits designed to qualitatively or quantitatively measure antibodies specific for a desired ligand. For example, the present invention encompasses recombinant mouse-human chimeric antibodies which may be used as calibrators (standards) and/or positive controls in assays and kits which measure human antibodies. Any species may be used in creating the chimeric antibodies, and the presence of any corresponding species of antibody may be detected.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

REAGENTS FOR USE AS CALIBRATORS AND CONTROLS

5 BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a method of using reagents as calibrators (standards) and/or controls in diagnostic assays and kits. More specifically, one or more of these reagents may be used in place of seropositive plasma or serum in the
10 production of calibrators and/or controls for diagnostic assays and kits designed to qualitatively or quantitatively measure antibodies specific for a desired ligand. The reagents themselves bind specifically to a predetermined ligand, contain one or more antibody constant region epitopes, and are homogeneous in specificity and affinity. The reagents may be produced by the use of hybridoma and/or
15 recombinant DNA technology.

Background Information

Antibodies are multidomain proteins composed of two identical light (L) and two identical heavy (H) polypeptide chains, linked together by disulfide bonds
20 (Figure 1). The amino terminal domain of both the L and H chains exhibits considerable diversity in amino acid sequence and conformation and is referred to as the variable (V) region. Residing within each V region are three segments of exceptional variability, referred to as hypervariable regions or complementarity-determining regions (CDRs), that form the ligand binding pocket. The other
25 domains of both the L and H chains constitute the constant regions. The constant regions are not involved in ligand binding and exhibit more limited variation. Constant regions are species specific and can be divided into various classes and subclasses based on differences in the heavy chain constant region including size, charge, amino acid composition, glycosylation and biological function
30 (Carayannopoulos, L. and Capra, J.D. Structure and Function of Immunoglobulins, In Fundamental Immunology, 3rd edition, Paul W.E. ed., Raven Press Ltd., New York, pgs. 283-314 (1993)).

The immune system generates a remarkably diverse repertoire of antibody molecules capable of recognizing virtually any substance. The primary antibody
35 response induced by challenge with antigen (i.e., any substance capable of eliciting an immune response, for example, proteins, carbohydrates, nucleic acids, lipids, or hapten conjugated to a carrier) results in the production of antibodies predominantly of the IgM class. This response is polyclonal in nature, as a heterogeneous mixture of antibodies against different epitopes of the antigen is
40 produced. Subsequent or prolonged challenge with the same antigen leads to a

secondary response characterized by significantly greater titers of antibody than that seen in the primary response that are generally higher in affinity (measure of the binding strength between an epitope and the antibody combining site) and composed almost entirely of the IgG class. The specific IgM titer generally wanes more rapidly than the specific IgG titer. As a result, monitoring the class of specific antibody present in serum or other biological fluids provides an indicator of the individual's immune status to a specific antigen (e.g., infectious agents). Antibody class can also be of clinical relevance in cases of autoimmunity and for monitoring Type I hypersensitivity (allergic responses) associated with production of IgE class antibodies (Roitt, I. ed., Immunology, Gower Medical Publishing Ltd., London, England (1985); Paul W.E. ed., Fundamental Immunology, 3rd edition, Raven Press Ltd., New York (1993)).

Irrespective of class, antibody molecules bind to ligands with high affinity and specificity (the ability to discriminate between the epitope to which it is directed and any other epitope) making them ideal immunodiagnostic reagents. Immunoassays provide a rapid and sensitive method to monitor for infectious agents, physiological function, allergy, autoimmunity, cancer, pharmaceuticals, and drugs of abuse. Manual and automated immunoassays have been designed to measure the antibody response in general, antibody to a specific antigen, and diagnostically relevant antigens or haptens. Heterologous immunoassays generally consist of multiple reaction steps and ultimately require separation of the immune complexed reactant from the free reactants to obtain the test result. In contrast, homogeneous immunoassays, are solution-phase systems that do not require the separation of complexed reactant from free reactants. Immunoassays have been developed with many different formats, but can be divided into two main classes: (1) competitive assays, and (2) non-competitive assays (e.g. immunometric, sandwich). For heterologous immunoassays of both classes, solid-phase biochemistry for separation of bound and free reactants has proven revolutionary. Antibody or antigen reagents can be covalently or non-covalently (e.g. ionic, hydrophobic) attached to the solid phase. Linking agents for covalent attachment are known and may be part of the solid phase or derivatized to it prior to coating. Examples of solid phases used in immunoassays are, porous and non-porous materials, latex particles, magnetic particles, microparticles, beads, membranes, microtiter wells and plastic tubes. The choice of solid phase material and method of labeling the antigen or antibody reagent is determined based on desired assay format performance characteristics. For some immunoassays, no label is required. For example, if the antigen is on a detectable particle such as a red blood cell, reactivity can be established based on agglutination. Alternatively, antigen-

antibody reaction may result in a visible change (e.g., radial immunodiffusion). In most cases, one of the antibody or antigen reagents used in an immunoassay is attached to a signal generating compound or "label". This signal generating compound or "label" is in itself detectable or may be reacted with one or more additional compounds to generate a detectable product. Examples of signal generating compounds include chromogens, radioisotopes (e.g. ^{125}I , ^{131}I , ^{32}P , ^3H , ^{35}S , and ^{14}C), fluorescent compounds (e.g. fluorescein, rhodamine), chemiluminescent compounds, particles (visible or fluorescent), nucleic acids, complexing agents, or catalysts such as enzymes (e.g. alkaline phosphatase, acid phosphatase, horseradish peroxidase, beta-galactosidase, and ribonuclease). In the case of enzyme use, addition of chromo-, fluoro- or lumino-genic substrate results in generation of a detectable signal. Other detection systems such as time-resolved fluorescence, internal-reflection fluorescence, amplification (e.g. polymerase chain reaction) and Raman spectroscopy are also useful.

Immunoassays have been developed to monitor biological fluids (e.g., plasma, serum, cerebrospinal fluid, saliva, tears, nasal washes, or aqueous extracts of tissues and cells) for the presence of antibody specific for an antigen of interest (e.g. infectious agent, autoantigen, allergen). In many cases, these specific antibody immunoassays have been designed to be antibody class or subclass specific. There are two general formats commonly utilized to monitor specific antibody in humans: (1) antigen is presented on a solid phase, the human biological fluid containing specific antibodies is allowed to react with the antigen, and then antibody bound to antigen is detected with an anti-human antibody coupled to a signal generating compound and (2) an anti-human antibody is bound to the solid phase, the human biological fluid containing specific antibodies is allowed to react with the antibody, and then antigen attached to a signal generating compound is added to detect specific antibody. In both formats, the anti-human antibody reagent can be polyclonal or monoclonal. Moreover, the anti-human antibody reagent may recognize all antibody classes, or alternatively, be specific for a particular class or subclass of antibody, depending upon the intended purpose of the assay. The reactivity of this reagent reflects the spectrum of antibodies of which it is composed and the particular antibody constant region epitopes to which they bind. Constant region epitopes are antigenic determinants to which an antibody response can be generated. Examples of constant region epitopes include: species invariant epitopes (class or subclass specific epitopes), and allotypic epitopes (present on some, but not all members of a species). Methods for manufacturing and testing of anti-human antibody reagents that bind to constant region epitopes are well known to the art. Assays for monitoring of specific

antibody response in other species could be designed in an analogous manner by one skilled in the art.

Immunoassays designed to detect specific antibody provide a measure of antibody activity. This may be referred to as antibody titer, e.g. mid-point or end-point titer, or expressed in units (activity or gravimetric) relative to a reference standard. Immunoassays and kits typically include one or more components containing the specific antibody being measured that function as calibrators (standards) and/or positive control. Calibrators (standards) are used to establish calibration (standard) curves for interpolation of antibody concentration, or alternatively, a single calibrator may be used near the positive/negative cutoff. The positive control is used to establish assay performance characteristics and is a useful indicator of the integrity of the reagents. In addition, immunoassays and kits to detect specific antibody generally include a negative control, such as serum or plasma, that contains no antibody reactive with the antigen of interest. Preferably, the calibrators and positive controls are prepared with the specific antibody being measured or a material chemically similar to it. Ideally the calibrator(s) and controls are manufactured to interact with the other assay components in a manner analogous to the test analyte (specific antibody). Calibrators and positive controls are generally manufactured by spiking known quantities of specific antibody derived from seropositive plasma or serum (polyclonal antibody) into the negative control reagent. Often times multiple calibrators are included that contain varying concentrations of specific antibody that span the range of concentrations the assay is designed to measure. Quantitative immunoassays may include up to 8 calibrators (standards) to establish a calibration (standard) curve from which results can be interpolated. The quantity of specific antibody assigned to the calibrator(s) and control(s) is standardized against primary reference standards. In the case of antibody activity, the reference standard is often established using individual or pooled sera that has been characterized empirically for characteristics such as quantity, quality, and specificity. The reference standard may be assigned relative units of activity or be a gravimetric quantity of antibody. For qualitative immunoassays, a single calibrator (standard) may be used that is set near the positive/negative cutoff. Some manufacturer's refer to the single calibrator (standard) as an index calibrator (Voller, A. *et. al.*, Immunoassays for the 80s, University Park Press, Baltimore (1981); Albertini, A. and Ekins, R., eds., Monoclonal Antibodies and Developments in Immunoassay, Elsevier/North-Holland Biomedical Press, New York (1981); Butler, J., ed., Immunochemistry of Solid-Phase Immunoassay, CRC Press, Boca Raton (1991)).

Two examples of an immunometric antibody-capture based immunoassay are the IMx Toxo IgM and Toxo IgG (Figure 2) antibody assays manufactured by Abbott Laboratories. Both assays are automated Microparticle Enzyme Immunoassay (MEIA) which measure antibodies to *Toxoplasma gondii* (*T. gondii*) in human serum or plasma (Safford, J.W. *et. al.*, J. Clin. Pathol. 44:238-242 (1991)). One assay qualitatively measures IgM antibodies, indicative of recent exposure or acute infection, and the other assay quantitatively measures IgG, indicative of chronic or past infection. *T. gondii*, an obligate intracellular parasite infecting adults often asymptotically, can lead to serious consequences for the fetus due to transplacental transmission which occurs during acute acquired maternal infection (Remington, J.S. and Krahenbuhl J.L., Comprehensive Immunology (A.J. Nahmias and O'Reilly. Eds.) pgs. 327-371. Plenum, New York/London (1982); Remington, J.S., Intrauterine Infections: Birth defects Origin. Ser 4:47-56. The National Foundation of the March of Dimes, New York (1968)). Determination of maternal immune status by testing for the presence of *T. gondii* specific IgM or IgG antibodies can aid in the determination of pregnancies at risk and in the case of seronegative individuals allows one to monitor for seroconversion that would be indicative of acute infection (Desmonts, G. and Couvreur J., New Engl. J. Med. 290:1110-1116 (1974); McCabe, R. and Remington J.S., New Engl. J. Med. 318:313-317 (1988); Sibalic, D. *et. al.*, Gynecol. Obstet. Invest. 36:91-95 (1993)). These assays use microparticles coated with *T. gondii* antigens as the solid phase. Specimen is added to the coated microparticles to allow antibodies specific for *T. gondii* to bind. Subsequently, an alkaline phosphatase conjugated anti-human IgM (or anti-human IgG) is added that binds specifically to IgM (or IgG) class antibodies complexed to the *T. gondii* antigens. Following addition of a suitable substrate, the rate of enzyme-catalyzed turnover is monitored based on fluorescence.

The calibrators and positive controls for the IgM and IgG anti-*T. gondii* assays are prepared from plasma collected from human donors reactive to *T. gondii*. High titer plasma or serum has traditionally served as a source of controls and/or calibrators (standards) in diagnostic assays and kits designed to monitor for the presence of human antibodies specific for a given antigen. These include tests to detect antibodies to human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, respiratory syncytial virus, Rubella virus, *Toxoplasma gondii*, *Trypanosoma cruzi*, *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Helicobacter pylori*, and *Streptococcus pyogenes*. Use of human

seropositive plasma or serum for the manufacture of calibrators (standards) and/or controls has several significant drawbacks, including: (1) the increasing difficulty of sourcing large volumes of plasma or serum with high titer, high specificity, and that lack antibodies to other infectious agents, (2) considerable lot-to-lot variability over time with respect to titer and specificity which impacts the performance of the assay, (3) inherent limitations with respect to characterization of an antisera due to its polyclonal nature (heterogeneous in antibody class, specificity and affinity), and (4) cost. In fact, it is conceivable that, in some cases, it may be impossible to maintain production of calibrators and/or controls that are based on seropositive human plasma due to sourcing issues. It can be especially difficult to find high titer sources of IgM antibody as these are generally obtained from acutely infected individuals. For example, sourcing of IgM reactive to Rubella in the U.S. is difficult due to the successful vaccination program. As sourcing of suitable seropositive plasma or serum becomes more difficult, the costs related to manufacturing of calibrators and controls increase, and this economic burden is ultimately passed on to the patient. An alternative method for manufacture of calibrators (standards) and/or positive controls for diagnostic assays and kits designed to monitor levels of specific antibody would represent a significant advance.

Genetically engineered antibodies, such as mouse:human chimeric antibodies, can be used as quality control reagents for specificity testing of anti-human antibody conjugates and for quality control of human total immunoglobulin immunoassays. It was further proposed that these chimeric antibodies may be useful reagents for quantitation of specific antibody in reference standards. The chimeric antibodies would be used to establish a heterologous dose-response curve to interpolate the amount of antibody in a reference standard specific for a different antigen (Hamilton, R.G., *Ann. Biol. Clin.* 48:473-477 (1990); Butler, J.E. and Hamilton, R.G., *In Immunochemistry of Solid-phase Immunoassay*, Butler, J.E. ed., CRC Press, Boca Raton, pgs. 173-198 (1991)). The term "heterologous" indicates that the antigen for which the chimeric antibodies are specific is defined, but unrelated to the antigen to which specific antibody is being monitored.

The present invention differs from the aforementioned in two important ways: (1) the proposed reagents are intended to be used, as a substitute for seropositive plasma or serum, in the manufacture of calibrators (standards) and/or positive controls for immunoassays and kits designed to monitor antigen specific antibody responses, and (2) the proposed reagents bind to the same or "homologous" antigen to that which the specific antibody being measured binds. Use of reagents which bind to the homologous antigen is preferable in that the

calibrator, positive control, and test specimen are reacted to the same antigen under identical conditions, providing a more realistic measure of specific antibody activity, and has the added advantage of allowing one to monitor the integrity of the test antigen at the time the assay is run.

5 One alternative source of material for the manufacture of positive controls in immunoassays designed to detect specific human antibody is non-human immune antibody that reacts with an anti-human antibody (U.S. Patent 5,008,183). Use of non-human immune (polyclonal) sera has several drawbacks including: (a) lot-to-lot variability over time with respect to antibody class
10 composition, titer, specificity and affinity that can impact assay performance; (b) difficulty in characterization due to its polyclonal composition (e.g. heterogeneous affinity and specificity); (c) limited supply; and (d) in the case of infectious agents, potential biohazard if live organisms are used to immunize.

An alternative source of material for the manufacture of calibrators and
15 controls for IgM assays is a composite antibody of a nonspecific IgM immunoglobulin moiety covalently linked to a specific non-IgM antibody moiety (U.S. Patent 5,478,753). Use of immune sera to produce the composite antibody has all of the inherent drawbacks outlined above. In addition, one must source and purify both the immune and non-immune moieties used to construct the composite
20 antibody. Moreover, the chemically crosslinked products would be heterogeneous with respect to the number and location of the attached non-immune antibody moieties. In fact, attachment near the binding site may result in steric interference of antigen binding by the specific antibody.

Use of the reagents described in the present invention, that bind to ligand,
25 contain one or more constant region epitopes, and are homogeneous in specificity and affinity (i.e., all molecules are uniform with respect to the properties of specificity and affinity), circumvent all of the problems associated with using an immune sera in manufacture of calibrators and positive controls. Furthermore, since the constant region epitopes are an integral part of the reagent (i.e., directly
30 fused to the ligand binding domain) a more uniform composition is obtained. Moreover, the present reagents can be readily and reproducibly generated in virtually unlimited quantities and are also useful for quantitating, and monitoring the integrity of, antigen used in the assay.

35

SUMMARY OF THE INVENTION

Traditionally, diagnostic assays and kits designed to detect the presence of human antibodies specific for a given antigen (e.g., human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human

T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus, Rubella virus, *Toxoplasma gondii*, *Trypanosoma cruzi*, *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Helicobacter pylori*, and *Streptococcus pyogenes*) have used seropositive human plasma (polyclonal antibody) or serum to manufacture calibrators (standards) and controls. In contrast, the present invention relates to a method of using reagents as calibrators (standards) and/or controls in such diagnostic assays and kits in place of such plasma or serum. More specifically, one or more of these reagents may be used in the place of seropositive plasma or serum as calibrators (standards) and/or controls for diagnostic assays and kits designed to qualitatively or quantitatively measure antibodies specific for a desired ligand. The reagents themselves bind specifically to a predetermined ligand, contain one or more antibody constant region epitopes, and are homogeneous or uniform in specificity and affinity. The agents may be produced by the use of hybridoma and/or recombinant DNA technology.

More specifically, the present invention encompasses a method for detecting the presence of antibody which may be present in a test sample wherein this method comprises (a) contacting the test sample suspected of containing the antibody with antigen specific for the antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) detecting the presence of the antibody which may be present in the test sample, and (c) employing, as a control or calibrator, a reagent which binds to the antigen, wherein the improvement comprises employing, as the control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein the reagent binds to the antigen and is homogeneous with respect to specificity and affinity.

The invention also includes a method for detecting the presence of antibody which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibody with antigen specific for the antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) detecting the presence of the antibody which may be present in the test sample, and (c) employing, as a control or calibrator, two or more reagents which bind to the antigen, wherein the improvement comprises employing, as the control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of the two or more reagents binds to different epitopes on said antigen and is homogeneous with respect to specificity and affinity.

Furthermore, the invention encompasses a method for detecting the presence of antibody which may be present in a test sample wherein the method

comprises (a) contacting the test sample suspected of containing the antibody with antigen specific for the antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) adding a direct or indirect conjugate to the resulting antigen/antibody complexes for a time and under conditions sufficient to allow the conjugate to bind to the bound antibody, wherein the conjugate comprises an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of the antibody which may be present in the test sample by detecting the signal generated by the signal generating compound, and (d) employing, as a control or calibrator, a reagent which binds to the antigen, wherein the improvement comprises employing, as said control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein the reagent binds to the antigen and is homogeneous with respect to specificity and affinity.

The present invention additionally includes a method for detecting the presence of antibody which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibody with antigen specific for the antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) adding a direct or indirect conjugate to the resulting antigen/antibody complexes for a time and under conditions sufficient to allow the conjugate to bind to the bound antibody, wherein said conjugate comprises an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of the antibody which may be present in said test sample by detecting the signal generated by the signal generating compound, and (d) employing, as a control or calibrator, two or more reagents which bind to the antigen, wherein the improvement comprises employing, as the control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of the two or more reagents binds to different epitopes on the antigen and is homogeneous with respect to specificity and affinity.

In all of the above methods, the reagent may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal antibody derived from a species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-

reactivity. The chimeric monoclonal antibody may comprise H and L chain variable regions derived from a rodent and H and L chain constant region genes derived from a human. Additionally, the chimeric monoclonal antibody may bind specifically to *Toxoplasma gondii* and more specifically to proteins P30 or P66 thereof.

In the methods involving one reagent, the H chain variable region of the chimeric monoclonal antibody, if such is the reagent, may be encoded by the nucleotide sequence shown in Figure 6 or allelic variations thereof, and the L chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 7 or allelic variations thereof. The H chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 6, and the L chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 7.

Alternatively, the H chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 8 or allelic variations thereof, and the L chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 9 or allelic variations thereof. The H chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 8, and the L chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 9.

In the methods above involving more than one reagent, wherein each is a chimeric monoclonal antibody, the H chain variable region representing one of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 6 or allelic variations thereof, and the L chain variable region of the chimeric monoclonal antibody representing the same one of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 7 or allelic variations thereof, and the H chain variable region of the chimeric monoclonal antibody representing another of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 8 or allelic variations thereof and the L chain variable region of this other of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 9 or allelic variations thereof.

The H chain variable region of the chimeric monoclonal antibody representing one of the two or more reagents has the amino acid sequence shown in Figure 6 and the L chain variable region of the chimeric monoclonal antibody representing the one of the two or more reagents may have the amino acid sequence shown in Figure 7, and the H chain variable region of the chimeric monoclonal antibody representing another of this two or more reagents may have

the amino acid sequence shown in Figure 8 and the L chain variable region of this other of the two or more reagents may have the amino acid sequence shown in Figure 9.

In the above methods, the antibody to be detected in the test sample is selected from the group consisting of IgA, IgD, IgE, IgG, and IgM. The antigen may be selected from the group consisting of an infectious agent, an autoantigen, an allergen, and a pharmaceutical compound. The infectious agent may be selected from the group consisting of a parasite, a bacterium, a fungus, a yeast and a virus. More specifically, the virus may be selected from the group consisting of: human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus, and Rubella virus. The parasite may be selected from the group consisting of *Toxoplasma gondii* and *Trypanosoma cruzi*. The fungus may be selected from the group consisting of *Histoplasma capsulatum* and *Cryptococcus neoformans*, and the bacterium may be selected from the group consisting of *Helicobacter pylori* and *Streptococcus pyogenes*.

The present invention also encompasses a kit for determining the presence of antibody in a test sample comprising: a) an antigen specific for the antibody; and b) a control or calibrator comprising a reagent wherein the reagent comprises one or more antibody constant region epitopes, binds to the antigen, and is homogeneous with respect to specificity and affinity.

The invention also includes a kit for determining the presence of antibody in a test sample comprising: a) an antigen specific for the antibody; and b) a control or calibrator comprising two or more reagents wherein each of the two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.

Additionally, the invention includes a kit for determining the presence of antibody in a test sample comprising: a) an antigen specific for the antibody; b) a direct or indirect conjugate comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and c) a control or calibrator comprising a reagent wherein the reagent comprises one or more antibody constant region epitopes, binds to the antigen, and is homogeneous with respect to specificity and affinity.

Furthermore, the invention includes a kit for determining the presence of antibody in a test sample comprising: a) an antigen specific for the antibody;

- b) a direct or indirect conjugate comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and c) a control or calibrator comprising two or more reagents wherein each of the two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on the antigen, and is homogeneous with respect to specificity and affinity.

In all of the above kits, the reagent may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal antibody derived from a species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-reactivity.

When the reagent is a chimeric monoclonal antibody, it comprises H and L chain variable regions derived from a rodent and H and L chain constant region genes derived from a human.

Furthermore, the antibody to be detected may be selected from the group consisting of IgA, IgD, IgE, IgG, and IgM. The antigen of the kits may be selected from the group consisting of an infectious agent, an autoantigen, an allergen, and a pharmaceutical compound. The infectious agent may be selected from the group consisting of a parasite, a bacterium, a fungus, a yeast and a virus. More specifically, the virus may be selected from the group consisting of: human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus and Rubella virus. The parasite may be selected from the group consisting of *Toxoplasma gondii* and *Trypanosoma cruzi*. The fungus may be selected from the group consisting *Histoplasma capsulatum* and *Cryptococcus neoformans*, and the bacterium may be selected from the group consisting of *Helicobacter pylori* and *Streptococcus pyogenes*.

Additionally, the present invention includes a method for detecting the presence of antibody which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibody with anti-antibody specific for the antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) detecting the

presence of the antibody which may be present in the test sample, and (c) employing, as a control or calibrator, a reagent which binds to the anti-antibody, wherein the improvement comprises employing, as the control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein the reagent binds to said antigen and is homogeneous with respect to specificity and affinity.

The invention also includes a method for detecting the presence of antibody which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibody with anti-antibody specific for the antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) detecting the presence of the antibody which may be present in the test sample, and (c) employing, as a control or calibrator, two or more reagents which bind to the anti-antibody, wherein the improvement comprises employing, as the control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of the two or more reagents binds to different epitopes on the antigen and is homogeneous with respect to specificity and affinity.

Additionally, the present invention includes a method for detecting the presence of antibody which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibody with anti-antibody specific for the antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) adding a conjugate to the resulting anti-antibody/antibody complexes for a time and under conditions sufficient to allow the conjugate to bind to the bound antibody, wherein the conjugate comprises an antigen attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of the antibody which may be present in the test sample by detecting the signal generated by the signal generating compound, and (d) employing, as a control or calibrator, a reagent which comprises antibody to the anti-antibody, wherein the improvement comprises employing, as the control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein the reagent binds to the antigen and is homogeneous with respect to specificity and affinity.

Furthermore, another method of the invention for detecting the presence of antibody which may be present in a test sample comprises (a) contacting the test sample suspected of containing the antibody with anti-antibody specific for the antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) adding a conjugate to the resulting anti-antibody/antibody complexes for a time and under conditions sufficient to allow

the conjugate to bind to the bound antibody, wherein the conjugate comprises an antigen attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of the antibody which may be present in the test sample by detecting the signal generated by the signal generating compound, and
5 (d) employing, as a control or calibrator, two or more reagents which bind to the anti-antibody, wherein the improvement comprises employing, as the control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of the two or more reagents binds to different epitopes on the antigen and has a unique specificity and affinity.

10 In the methods presented directly above, the reagent may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal
15 antibody derived from a species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-reactivity.

20 If the reagent is a chimeric monoclonal antibody, it comprises H and L chain variable regions derived from a rodent and H and L chain constant region genes derived from a human. The chimeric monoclonal antibody may bind specifically to *Toxoplasma gondii*. More specifically, the chimeric monoclonal antibody may bind to protein P30 or protein P66 of *Toxoplasma gondii*.

25 In the methods involving one reagent, where the reagent is a chimeric monoclonal antibody, the H chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 6 or allelic variations thereof, and the L chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 7 or allelic
30 variations thereof. The H chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 6, and the L chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 7.

Alternatively, the H chain variable region of the chimeric monoclonal
35 antibody may be encoded by the nucleotide sequence shown in Figure 8 or allelic variations thereof, and the L chain variable region of the chimeric monoclonal antibody may be encoded by the nucleotide sequence shown in Figure 9 or allelic variations thereof. The H chain variable region of the chimeric monoclonal

15

antibody may have the amino acid sequence nucleotide shown in Figure 8, and the L chain variable region of the chimeric monoclonal antibody may have the amino acid sequence shown in Figure 9.

5 In the methods where more than one reagent is involved, the H chain variable region of the chimeric monoclonal antibody representing one of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 6 or allelic variations thereof and the L chain variable region of the chimeric monoclonal antibody representing that one of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 7 or allelic variations thereof, and the H
10 chain variable region of the chimeric monoclonal antibody representing another of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 8 or allelic variations thereof and the L chain variable region of this other of the two or more reagents may be encoded by the nucleotide sequence shown in Figure 9 or allelic variations thereof. The H chain variable region of the chimeric
15 monoclonal antibody representing one of the two or more reagents may have the amino acid sequence shown in Figure 6 and the L chain variable region of the chimeric monoclonal antibody representing this one of the two or more reagents may have the amino acid sequence shown in Figure 7, and the H chain variable region of the chimeric monoclonal antibody representing another of the two or
20 more reagents may have the amino acid sequence shown in Figure 8 and the L chain variable region of this other of the two or more reagents may have the amino acid sequence shown in Figure 9.

The antibody to be detected in said test sample may be selected from the group consisting of IgA, IgD, IgE, IgG, and IgM. The antigen may be selected
25 from the group consisting of an infectious agent, an autoantigen, an allergen, and a pharmaceutical compound. The infectious agent may be selected from the group consisting of a parasite, a bacterium, a fungus, a yeast and a virus. More specifically, the virus may be selected from the group consisting of: human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell
30 leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus, and Rubella virus. The parasite may be selected from the group consisting of *Toxoplasma gondii* and *Trypanosoma cruzi*. The fungus may be selected from the group consisting of
35 *Histoplasma capsulatum* and *Cryptococcus neoformans*, and the bacterium may be selected from the group consisting of *Helicobacter pylori* and *Streptococcus pyogenes*.

16

The invention also includes a kit for determining the presence of antibody in a test sample comprising: a) an anti-antibody specific for the antibody; b) an antigen specific for the antibody; and c) a control or calibrator comprising a reagent wherein the reagent comprises one or more antibody constant region epitopes, binds to the antigen, and is homogeneous with respect to specificity and affinity.

Additionally, the invention includes a kit for determining the presence of antibody in a test sample comprising: a) an anti-antibody specific for the antibody; b) an antigen specific for the antibody; and c) a control or calibrator comprising two or more reagents wherein each of the two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.

Furthermore, the invention encompasses a kit for determining the presence of antibody in a test sample comprising: a) an anti-antibody specific for the antibody; b) a direct or indirect conjugate comprising an antigen attached to a signal generating compound capable of generating a detectable signal; and c) a control or calibrator comprising a reagent wherein the reagent comprises one or more antibody constant region epitopes, binds to the antigen, and is homogeneous with respect to specificity and affinity.

The invention also includes a kit for determining the presence of antibody in a test sample comprising: a) an anti-antibody specific for the antibody; b) a direct or indirect conjugate comprising an antigen attached to a signal generating compound capable of generating a detectable signal; and c) a control or calibrator comprising two or more reagents wherein each of the two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.

In the kits directly above, the reagent may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal antibody derived from a species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-reactivity.

If a chimeric monoclonal antibody is the reagent in each of the kits, it comprises H and L chain variable regions derived from a rodent and H and L chain constant region genes derived from a human.

The antibody to be detected in test sample may be selected from the group consisting of IgA, IgD, IgE, IgG and IgM. The antigen is selected from the group consisting of an infectious agent, an autoantigen, an allergen, and a pharmaceutical compound. The infectious agent may be selected from the group consisting of a parasite, a bacterium, a fungus, a yeast and a virus. More specifically, the virus may be selected from the group consisting of: human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus and Rubella virus. The parasite may be selected from the group consisting of *Toxoplasma gondii* and *Trypanosoma cruzi*. The fungus may be selected from the group consisting of *Histoplasma capsulatum* and *Cryptococcus neoformans*, and the bacterium may be selected from the group consisting of *Helicobacter pylori*, and *Streptococcus pyogenes*.

The invention also encompasses a method for detecting the presence of antibodies, developed against more than one antigen, which may be present in a test sample wherein the method comprises (a) contacting the test sample suspected of containing the antibodies with antigens specific for the antibodies, respectively, for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) adding direct or indirect conjugates to the antigen/antibody complexes for a time and under conditions sufficient to allow the conjugates to bind to the bound antibodies, wherein the conjugates comprise an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of the antibodies which may be present in the test sample by detecting the signal generated by the signal generating compound, and (d) employing, as controls or calibrators, reagents which bind to the antigens, wherein the improvement comprises employing, as the controls or calibrators, reagents, each comprising one or more antibody constant region epitopes, wherein each of the reagents bind to said antigens, respectively, and is homogeneous with respect to specificity and affinity.

Each of the reagents may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal antibody derived from a

species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-reactivity.

5 The features noted above with respect to all of the other methods apply to this method as well.

 The invention also includes a kit for determining the presence of antibodies, developed against more than one antigen, which may be present in a test sample, comprising: a) antigens specific for the antibodies, respectively;
10 b) direct or indirect conjugates each comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and c) controls or calibrators comprising reagents wherein each of the reagents comprises one or more antibody constant region epitopes, bind to the respective antigens, and is homogeneous with respect to specificity and affinity.

15 In this kit, each of the reagents may be selected from the group consisting of a chimeric monoclonal antibody comprising H and L chain variable regions from one host species fused to constant region genes derived from the same host species as the antibody being measured, a monoclonal antibody derived from the same host species as the antibody being measured, a monoclonal antibody derived
20 from a species related on the basis of immunologic cross-reactivity to that being assayed, and a polypeptide fused to an antibody constant region or a fragment thereof derived from the same host species as the antibody being measured or related to the host species on the basis of immunologic cross-reactivity.

 The features noted above with respect to the other kits apply to this kit as
25 well.

BRIEF DESCRIPTION OF THE DRAWINGS

 Figure 1 illustrates the basic structure of an antibody molecule. The two identical heavy (H) chains are composed of either four or five domains (depending
30 on the class of the antibody) and a hinge region, while the light (L) chains are composed of two domains. The amino terminal domain of the H and L chains is referred to as the variable (V) region and is responsible for antigen binding activity. The other domains present in the H and L chain constitute the constant region. This is a depiction of a mouse-human chimeric antibody as mouse V
35 regions are joined to human constant regions.

 Figure 2 depicts the steps involved in the Abbott IMx Toxo IgG automated antibody capture-type immunoassay.

Figure 3 represents the antibody expression vector pdHL2 which contains human IgG1 (hu C γ 1) and human kappa constant region genes (hu C κ) in their genomic configuration. Both transcription units contain an upstream immunoglobulin H chain enhancer element (E_H) and mouse metallothionein I promoter (P_{MT}). Insertion of V κ region (*Xba* I - *Bam* HI) and V_H region (*Xho* I - *Hind* III) cassettes results in expression of complete antibody. The vector also contains a bacterial origin of replication (ori) and β -lactamase (amp) gene derived from the plasmid pBR322 and an altered mouse dihydrofolate reductase (DHFR) gene under the control of the SV40 early region enhancer, promoter and polyadenylation (poly A) signal sequences. The DHFR marker gene allows for selection and amplification in mammalian cells with methotrexate. The chimeric IgM construct pJH2-24-95B1 is a modified version of pdHL2. In pJH2-24-95B1, the stuffer fragment located between the *Xba* I and *Bam* HI sites has been replaced by the 5-465-210 V κ cassette (Figure 7). The 5-465-210 V_H cassette (Figure 6) has been substituted for the stuffer fragment located between the *Xho* I and *Hind* III sites. In addition, the human IgG1 has been replaced by a genomic clone of the human IgM constant region (hu C μ) gene. The hu C μ clone extends from *Spe* I to the *Eco* RV/*Pvu* II junction. Restriction site abbreviations are: B, *Bam* HI; H, E, *Eag* I; EV, *Eco* RV; *Hind* III; P, *Pvu* II; SII, *Sac* II; S, *Sal* I; Sp, *Spe* I; Xb, *Xba* I; and Xh, *Xho* I.

Figure 4 shows a diagrammatic representation of the key steps involved in generating the expression construct pJH2-24-95B1. This expression vector encodes a mouse-human chimeric IgM antibody comprised of H and L chain V regions from the mouse hybridoma 5-465-210 and human constant region genes. The chimeric antibody is specific for P30 of *T. gondii*.

Figure 5 represents a summary of the strategy used to construct the expression vector pJH3-19-95A. This expression construct encodes a mouse-human chimeric IgM antibody with H and L chain V regions derived from the mouse hybridoma 1-706-139 and human constant region genes. This chimeric IgM antibody binds selectively to P66 of *T. gondii*.

Figure 6 illustrates the nucleotide sequence of the V_H cassette containing the V_H cDNA cloned from hybridoma 5-465-210 (see SEQ ID NO:2). The deduced amino acid sequence is indicated by a single letter symbol below (see SEQ ID NO:1). The first amino acid of the mature protein is designated (+1), the splice

point of J_H2 to the constant region is indicated by the arrow, and the complementarity determining regions (CDRs) as defined by Kabat E.A. *et.al.*, (Sequences of Proteins of Immunological Interest, 5th edition, U.S. Department of Health and Human Services, Bethesda, MD (1991)) are indicated. The degenerate sense primer used to PCR amplify this V_H fragment from cDNA extended to nucleotide 41. Other features of note: (1-39), sense transfer primer with cloning site (*Xho* I); (16-72), leader sequence; (73-366), H chain V- gene; (367-384), H chain D segment; (385-429), H chain J_H2-minigene; (430-447), splice site sequence and *Hind* III cloning site derived from the antisense transfer primer.

Figure 7 represents the nucleotide sequence of the V_L cassette containing the V_K cDNA cloned from hybridoma 5-465-210 (see SEQ ID NO:4). The deduced amino acid sequence is indicated by a single letter symbol (see SEQ ID NO:3). The first amino acid of the mature protein is designated (+1), the splice point of J_K2 and the C_K gene is indicated by the arrow, and CDRs designated as in Fig. 6 are indicated. The sense primer used to PCR amplify the V_K region from cDNA extended to position 45. Additional sequences of note: (1-40), sense transfer primer sequences including the *Xba* I cloning site; (17-76), leader sequence; (77-373), κ chain V-gene; (374-409), J_K-minigene; (410-428), splice site sequence and *Bam* HI cloning site incorporated into the antisense transfer primer.

Figure 8 shows the nucleotide sequence of the V_H cassette containing the V_H cDNA cloned from the hybridoma 1-706-139 (see SEQ ID NO:6). The deduced amino acid sequence is shown by a single letter symbol (see SEQ ID NO:5). The first amino acid of the mature protein is designated (+1), the splice junction between J_H4 and the constant region is marked with an arrow, and CDRs determined as in Fig. 6 are indicated. The degenerate primer (sense) used to PCR amplify the V_H cDNA extended to position 41. Additional noteworthy features include: (1-35), sense transfer primer including the *Xho* I cloning site and the 5' end of the leader sequence, (12-68) leader sequence; (69-362), H chain V-gene; (363-380), presumed D-minigene sequence*; (381-434), J_H4-minigene; (434-452) splice and *Hind* III cloning sites incorporated into the antisense transfer primer.

*The exact boundary between the D and J-minigenes could not be determined.

Figure 9 represents the nucleotide sequence of the V_L cassette containing the V_K region cloned from hybridoma 1-706-139 (see SEQ ID NO:8). The deduced amino acid sequence is given in the single letter format (see SEQ ID

NO:7). The first amino acid of the mature protein is indicated (+1), the splice point between the J κ 1-minigene and the C κ gene is identified with an arrow, and CDRs determined as in Fig. 6 are designated. The 3' terminus of the degenerate sense primer used for PCR amplification of the V κ region from cDNA is at position 42. Other features include: (1-39), sense transfer primer sequence incorporating the *Xba* I cloning site and 5' leader sequences; (13-69) leader sequences; (70-368), κ V-gene; (369-405), J κ 1-minigene; (406-424), splice and *Bam* HI cloning sites incorporated into the antisense transfer primer.

Figure 10 shows a calibration curve for the anti-P66 chimeric IgG as compared with the positive human serum derived calibrator in the IMx Toxo IgG assay. Rate counts (counts/sec/sec) are shown on the Y-axis.

Figure 11 illustrates a calibration curve obtained for the anti-P66 chimeric IgM antibody as compared to the positive human serum derived calibrator in the IMx Toxo IgM assay. The index calibrator of 710 rates (rate counts = counts/sec/sec) was matched by the anti-P66 chimeric IgM at a concentration of 12.3 μ g/ml.

Figure 12 represents a calibration curve for the anti-P30 chimeric IgG as compared with positive human serum currently used as the calibrator in the IMx Toxo IgG assay. Rate counts (counts/sec/sec) are shown on the Y-axis.

Figure 13 illustrates a dilution curve run on the IMx for the anti-P30 chimeric IgM antibody along with positive human serum for the calibrators. The index calibrator of 560 rates (rate counts = counts/sec/sec) was successfully matched by the anti-P30 chimeric IgM at a concentration of 8.4 μ g/ml.

Figure 14 represents an accelerated stability analysis run on all reagents at 45°C at the B calibrator level (0.0036 mg/ml anti-P30 + 0.010 mg/ml anti-P66). No difference was observed for the chimeric IgG recombinant antibodies as compared to the human serum calibrator. However, by day 12, 40% of the P30 epitope on the microparticles is no longer recognized by the anti-P30 chimeric antibody. r = assay reagents; c = calibrator

Figure 15 shows an accelerated stability analysis of reagents stored at 45°C using F calibrator dilutions (0.11 mg/ml anti-P30 + 0.305 mg/ml anti-P30). No difference was observed for the chimeric IgG recombinant antibodies as compared

22

to the human serum calibrator. However, by day 12, 40% of the P30 epitope on the microparticles is no longer recognized by the anti-P30 chimeric antibody. r = assay reagents; c = calibrator

5 Figure 16 illustrates a comparison of a mixture of monoclonal antibodies equivalent to the B calibrator (0.0037 mg/ml anti-P30 IgG1 + 0.020 mg/ml anti-P66 IgG1) or F calibrator (0.11 mg/ml anti-P30 IgG1 and 0.61 mg/ml anti-P66 chimeric IgG1) with calibrators (cals) manufactured with positive human serum versus 7 independent antigen (Ag) lots. r = assay reagents; c = calibrator

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of using reagents as calibrators (standards) and/or controls in diagnostic kits and assays. More specifically, one or
15 more of these reagents may be used in place of plasma or serum in the production of calibrators and controls for diagnostic kits and assays designed to qualitatively or quantitatively measure antibodies specific for a desired ligand. The reagents themselves bind specifically to a predetermined ligand, contain one or more antibody constant region epitopes, and are uniform in specificity and affinity. The
20 reagents may be produced continually by the use of hybridoma and/or recombinant DNA technology.

There are several embodiments of the above-identified reagent. These embodiments are, for example, as follows:

- 1) a chimeric monoclonal antibody comprising H and L chain
25 variable regions from one host species fused to the constant region genes derived from the same host species as the antibody being measured;
- 2) a monoclonal antibody derived from the same host species as the antibody being measured;
- 3) a monoclonal antibody derived from a species related on the
30 basis of immunologic cross-reactivity to that being assayed; and
- 4) a polypeptide which binds specifically to a predetermined ligand fused to an antibody constant region or some part of a constant region of the desired host species.

35 The above-listed embodiments are described in detail below:

1) CHIMERIC MONOCLONAL ANTIBODIES:

In this embodiment of the invention, the reagent(s) used as a calibrator or control in the diagnostic assay or kit is a chimeric monoclonal antibody molecule comprising H and L chain V regions from one host species fused to H and L chain constant region genes from another host species. The H and L chain V regions may be derived from any vertebrate that produces antibody, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. The source of the antibody V regions, and method by which they are derived is based primarily on convenience and technology known to those of ordinary skill in the art. For example, the H and L chain V regions (comprising the part of the antibody molecule responsible for ligand binding activity) may be isolated from: single B cells, B cell hybridomas, B cells propagated *in vitro*, or B cells propagated *in vivo*, for example, human B cells in SCID mice (Simonsson, A.C. *et. al.*, Bio/Techniques 18(5):862-869 (1995); Banchereau, J. *et. al.*, Science 251:70-72 (1991); Amoroso, K. and Lipsky, P.E., J. Immunol. 145:3155-3161 (1990); Duchosal, M.A. *et. al.*, Nature 355:258-262 (1992)). Antibody V regions may be cloned by standard procedures known in the art, or modifications of these procedures. For instance, the V regions may be cloned according to the process described in Example III below.

Alternatively, antibody H and L chain V region sets with desired binding activity may be screened for by expression as, for example, Fab fragments (heterodimers of V_H and the first domain of the heavy chain constant region, and the complete light chain), Fv fragments (heterodimers of the H and L chain V region domains), or single-chain Fv (heterodimers of V_H and V_L domains connected by a peptide linker), in bacteria, e.g. *E. coli*, or selected through the use of combinatorial libraries expressed in lambda phage, on the surface of bacteriophage, on the surface of bacteria, or screened by display on any other biological (e.g. retrovirus or polysome) or non-biological system (Better, M. *et. al.*, Science, 240:1041-1043 (1988); Skerra, A. and Pluckthun, A., Science, 240:1038-1041 (1988); Huse, W.D. *et. al.*, Science 246:1275-1281 (1989); McCafferty, J. *et. al.*, Nature 348:552-554 (1990); Kang, A.S. *et. al.*, Proc. Natl. Acad. Sci. USA 88: 4363-4366 (1991); Fuchs P. *et. al.*, Bio/Technology 9:1369-1372 (1991); Francisco, J. *et. al.*, Proc. Natl. Acad. Sci. USA 90:10444-10448 (1993); Mattheakis, L.C. *et. al.*, Proc. Natl. Acad. Sci. USA 91:9022-9026 (1994)). The libraries may be composed of: native V regions isolated from an immunized or unimmunized host, synthetic or semi-synthetic V regions, or

modified V regions (Marks, J.D. *et al.*, J. Mol. Biol. 222:581-597 (1991); Barbas, C.F. III *et al.*, Proc. Natl. Acad. Sci. USA 89:4457-4461 (1992)). Examples of the latter include fine-tuning of specificity and/or affinity by *in vitro* mutagenesis.

- 5 The most critical property of the antibody V region combination (H and L) is that it forms a binding site with the desired properties of specificity and affinity for the ligand. Required specificity and affinity will be dictated by the intended use, and dependent upon such characteristics as assay format and desired performance characteristics (e.g. sensitivity, specificity, precision, and
10 parallelism). For example, if one requires a calibrator or control antibody specific for one particular immunodominant epitope (ligand) on an antigen, to mimic the serologic response *in vivo*, the H and L chain V region set used to generate the chimeric antibody can be chosen on this basis.

- Antibody constant region genes may be derived from any vertebrate species
15 including but not limited to rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. The choice of host species is dictated by the intended purpose. The antibody constant region is derived from the same host species, or one that is closely related, to the antibody being measured.

- 20 Chimeric monoclonal antibodies can be produced through the use of recombinant DNA techniques. For example, chimeric antibodies can be generated by targeted homologous recombination (Pell, H.P. *et al.*, Proc. Natl. Acad. Sci. USA 86:8507-8511 (1989)). Alternatively, antibody H and L chain V region genes may be cloned into a mammalian expression vector(s) containing antibody H
25 and L chain constant region genes derived from a different host species. Introduction of the expression construct(s) into appropriate host cells results in production of complete chimeric antibodies of a defined specificity (Morrison, S.L. *et al.*, Proc. Natl. Acad. Sci. USA 81: 6851-6855 (1984)). Many eukaryotic antibody expression vectors that are either stably integrated or exist as
30 extrachromosomal elements have been described and are known to those of ordinary skill in the art. The H and L chain transcription units can be introduced into the host cell individually on separate plasmids or together on the same vector.

- One example of an antibody expression vector is the plasmid, pdHL2 (Figure 3), which contains human IgG1 (hu C γ 1) and human kappa constant
35 region (hu C κ) genes in their genomic configuration (Gillies, S.D. *et al.*, J. Immunol. Methods 125:191-202 (1989)). Both transcription units contain an upstream immunoglobulin H chain enhancer element (E_H) and mouse metallothionein I promoter. Insertion of V κ region and V_H region cassettes results

in expression of complete antibody. Each V gene cassette includes a 5' immunoglobulin leader sequence and a splice donor site 3' of the V gene. The vector also contains a bacterial origin of replication and β -lactamase gene derived from the plasmid pBR322 and an altered mouse dihydrofolate reductase (DHFR) gene under the control of the SV40 early region enhancer, promoter and polyadenylation signal sequences. The DHFR marker gene allows for selection and amplification in mammalian cells with methotrexate.

Expression vectors used to produce chimeric antibodies may be modified to contain any constant region gene(s) (for example in humans: κ , λ , IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE) isolated from any vertebrate species that makes antibodies, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. By definition, the host species from which the H and L chain V regions are derived will be different than that from which the antibody constant regions are derived.

Depending on the vector system utilized, many different immortalized cell lines may serve as suitable hosts, these include but are not limited to: myeloma (e.g. X63-Ag8.653), hybridoma (Sp2/0-Ag14), lymphoma and Chinese Hamster Ovary (CHO) cells. Expression constructs can be introduced using a variety of techniques, including but not limited to, calcium phosphate precipitation, protoplast fusion, lipofection, retrovirus-derived shuttle vectors, and electroporation. Proper expression leads to secretion of the recombinant antibody into the medium. Alternatively, cells may be lysed and antibody subsequently purified.

Chimeric antibody molecules or fragments thereof could also be produced in other systems, including but not limited to: baculovirus, yeast, bacteria such as *E. coli*, and *in vitro* in cell-free systems such as rabbit reticulocyte lysate (Hasemann, C. and Capra, J.D. Proc. Natl. Acad. Sci. USA 87:3942-3946 (1990); Horwitz, A.H. *et al.*, Proc. Natl. Acad. Sci. USA 85:8678-8682 (1988); Pluckthun, A., Bio/Technology 9:545-551 (1991); Nicholls *et al.*, J. Biol. Chem. 268(7):5302-5308 (1993)).

In summary, a chimeric monoclonal antibody comprises at least two (e.g., IgG) and up to 10 (e.g. pentameric IgM) identical binding sites derived from the H and L chain V regions of one host species joined to the H and L chain antibody constant regions of another host species. The H and L chain V regions are responsible for the specificity and affinity of binding to the desired ligand. The source of the H and L chain constant regions is determined by the host species of antibody to be measured, in that it is preferably identical to it. The constant

regions have no ligand-binding activity, but provide serologically identifiable epitopes (ligands) specific to the particular constant region, thus providing a means to discriminate it from other constant regions. Expression of the H and L chain genes encoding the chimeric antibodies in, for example, an immortalized host cell such as Sp2/0-Ag14, results in production of monoclonal chimeric antibody of predetermined and uniform specificity and affinity. Thus, a continuous source of chimeric antibody with V regions of a single defined binding specificity, and H and L chain constant region epitopes, is provided. One or more of these reagents would be useful as calibrators and/or controls in diagnostic assays and kits designed to qualitatively or quantitatively measure levels of specific antibody.

One particular example of this embodiment is a recombinant chimeric antibody containing murine H and L chain V regions fused to human H and L chain constant regions for use as a calibrator and/or control. This embodiment of the invention is illustrated in detail in the examples which follow the description of embodiment (4).

2) MONOCLONAL ANTIBODIES DERIVED FROM THE SAME HOST SPECIES AS THE ANTIBODIES BEING MEASURED:

In this embodiment of the invention, the monoclonal antibodies may be derived from any vertebrate, mammalian species or otherwise that makes antibodies such as: rodent (i.e., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape, and human. The host species chosen is in accordance with the intended purpose of the assay or kit.

For example, if human antibodies are being measured, the monoclonal antibodies may be established from human B cells by traditional hybridoma technology as mouse:human heterohybridomas, human:human hybridomas, or by some other means of immortalization such as by Epstein-Barr Virus infection (Nowinski, R. *et. al.*, Science 210:537-539 (1980); Olsson, L. and Kaplan, H.S., Proc. Natl. Acad. Sci. USA 77:5429-5431 (1988); Rosen, A.M. *et. al.*, Nature 267:52-54 (1977)). The recent creation of transgenic mice carrying genomic clones of part of the human H and L chain immunoglobulin loci provides the opportunity to also establish mouse:mouse hybridomas secreting monoclonal human antibodies of desired specificities (Lonberg, N. *et. al.*, Nature 368:856-859 (1994); Green, L.L. *et. al.*, Nature Genetics 7:13-21 (1994)).

Human antibodies may also be created through the use of recombinant DNA technology. For example, the H and L chain V regions (comprising the part of the antibody molecule responsible for ligand binding activity) may be isolated from single human B cells, human B cells propagated *in vitro*, or human B cells

propagated in SCID mice (Simonsson, A.C. *et al.*, Bio/Techniques 18(5):862-869 (1995); (Banchereau, J. *et al.*, Science 251:70-72 (1991); Amoroso, K. and Lipsky, P.E., J. Immunol. 145:3155-3161 (1990); Duchosal, M.A. *et al.*, Nature 355:258-262 (1992)). Antibody V regions may be cloned by standard procedures known in the art, or modifications of these procedures. For instance, the V regions may be cloned according to the process described in Example III below.

Alternatively, human H and L chain V region sets with desired binding activity may be screened for as, for example, Fab fragments, Fv fragments, or single-chain Fv, by expression in bacteria, e.g. *E. coli*, or selected through the use of combinatorial libraries expressed in lambda phage, on the surface of bacteriophage, on the surface of bacteria, or screened by display on any other biological (e.g. retrovirus or polysome) or non-biological system (Better, M. *et al.*, Science, 240:1041-1043 (1988); Skerra, A. and Pluckthun, A., Science, 240:1038-1041 (1988); Huse, W.D. *et al.*, Science 246:1275-1281 (1989); McCafferty, J. *et al.*, Nature 348:552-554 (1990); Kang, A.S. *et al.*, Proc. Natl. Acad. Sci. USA 88: 4363-4366 (1991); Fuchs P. *et al.*, Bio/Technology 9:1369-1372 (1991); Francisco, J. *et al.*, Proc. Natl. Acad. Sci. USA 90:10444-10448 (1993); Mattheakis, L.C. *et al.*, Proc. Natl. Acad. Sci. USA 91:9022-9026 (1994)). The antibody libraries may consist of: native V regions from an immunized or unimmunized human, synthetic or semi-synthetic V regions, or modified V regions (Marks, J.D. *et al.*, J. Mol. Biol. 222:581-597 (1991); Barbas, C.F. III *et al.*, Proc. Natl. Acad. Sci. USA 89:4457-4461 (1992)). Examples of the latter include fine-tuning of specificity and/or affinity by *in vitro* mutagenesis. The primary basis for selecting the V regions is on the basis of their ligand-binding characteristics.

If human antibodies are being measured, the human H and L chain V region genes are cloned into a mammalian expression vector containing human H and L chain constant region genes. Introduction of the expression construct(s) into suitable host cells results in production of complete human antibodies of a defined specificity (Dorai, H. *et al.*, Hybridoma 11(5):667-675 (1992)). Many eukaryotic expression vectors for antibody have been described that are either stably integrated or exist as extrachromosomal elements, and these are known to those of ordinary skill in the art. The H and L chain transcription units can be introduced into the host cell individually on separate plasmids or together on the same vector.

One example of a suitable expression vector is the plasmid, pdHL2 (Figure 3), that contains human IgG1 (hu C γ 1) and human kappa constant region (hu C κ) genes in their genomic configuration (Gillies, S.D. *et al.*, J. Immunol. Methods 125:191-202 (1989)). Both transcription units contain an upstream

immunoglobulin H chain enhancer element (E_H) and mouse metallothionein I promoter. Insertion of V_K region and V_H region cassettes results in expression of complete antibody. Each V gene cassette includes a 5' immunoglobulin leader sequence and a splice donor site 3' of the V gene. The vector also contains a
5 bacterial origin of replication and β -lactamase gene derived from the plasmid pBR322 and an altered mouse dihydrofolate reductase (DHFR) gene under the control of the SV40 early region enhancer, promoter and polyadenylation signal sequences. The DHFR marker gene allows for selection and amplification in mammalian cells with methotrexate.

10 Antibody expression vectors may be modified to contain any of the constant region genes (in the case of humans: κ , λ , IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE) isolated from any vertebrate species that makes antibodies, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee),
15 and human. Similarly, antibody H and L chain V regions can be isolated from any vertebrate species that makes antibodies, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. Introduction of H and L chain V regions into an antibody expression vector containing H and L chain constant regions derived
20 from the same host species, results in formation of recombinant monoclonal antibody. Thus, monoclonal antibodies of any class or subclass can be produced from any vertebrate species that makes antibodies through the use of recombinant DNA, hybridoma, or a combination of these technologies. The host species chosen is in accordance with the intended purpose of the assay.

25 Depending on the expression vector(s), many different immortalized cell lines may serve as suitable hosts, these include but are not limited to: myeloma (e.g. X63-Ag8.653), hybridoma (Sp2/0-Ag14), lymphoma and Chinese Hamster Ovary (CHO) cells. Expression constructs can be introduced using a variety of techniques, including but not limited to, calcium phosphate precipitation,
30 protoplast fusion, lipofection, retrovirus-derived shuttle vectors, and electroporation. Proper expression leads to secretion of the recombinant antibody into the medium. Alternatively, cells may be lysed and antibody subsequently purified.

35 Antibody molecules or fragments thereof could also be produced in other systems, including but not limited to: baculovirus, yeast, bacteria such as *E. coli*, and *in vitro* in cell-free systems such as rabbit reticulocyte lysate (Hasemann, C. and Capra, J.D. Proc. Natl. Acad. Sci. USA 87:3942-3946 (1990); Horwitz, A.H. *et. al.*, Proc. Natl. Acad. Sci. USA 85:8678-8682 (1988); Pluckthun, A.

Bio/Technology 9:545-551 (1991); Nicholls *et. al.*, J. Biol. Chem. 268(7):5302-5308 (1993)).

Monoclonal antibodies produced by hybridoma, recombinant DNA, or a combination of these technologies may contain at least two (e.g. IgG) and up to 10 (e.g. pentameric IgM) identical binding sites with specificity and affinity to the desired ligand determined by the H and L chain V regions. The complete antibodies contain the entire H and L chain constant regions and thus all of the associated antigenic epitopes. Moreover, the antibodies are monoclonal thus are of a single-defined specificity and affinity and can be produced in unlimited quantities. One or more of these reagents may be used as calibrators and/or controls in diagnostic assays and kits designed to qualitatively or quantitatively measure levels of specific antibody.

3) A MONOCLONAL ANTIBODY DERIVED FROM A SPECIES RELATED
ON THE BASIS OF IMMUNOLOGIC CROSS-REACTIVITY, TO THAT
BEING ASSAYED:

An additional embodiment of the invention includes a monoclonal antibody derived from a closely related species to that being assayed. Species relatedness is defined on the basis of immunological cross-reactivity of constant region epitopes. At least one constant region epitope is the same or substantially the same to that of the species being assayed. The shared epitope(s) may not be chemically identical, but exhibit a chemical resemblance in 3-dimensional structure. The monoclonal antibodies may be derived from any vertebrate, mammalian species or otherwise that makes antibodies such as: rodent (i.e., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape, and human. The host species chosen is in accordance with the intended purpose of the assay and on the basis of reactivity with the reagent that binds specifically to one or more constant region epitopes of the species of antibody to be assayed.

For example, if one is measuring human antibody, a monoclonal antibody generated from another primate such as the chimpanzee may suffice as a calibrator or control. The differences at a molecular level between antibody constant region sequences of chimpanzee and human are roughly equivalent to those between allotypes of human (Ehrlich, P.H. *et. al.*, Hum. Antibod. Hybridomas 1:23-26 (1990); Ehrlich, P.H. *et. al.*, Mol. Immunol. 28:319-322 (1991)). Monoclonal antibodies may be derived from chimpanzee through the use of hybridoma or recombinant DNA technology. In the latter case, H and L chain V regions (comprising the part of the antibody molecule responsible for ligand binding activity) may be isolated from single chimpanzee B cells, chimpanzee B cells

propagated *in vitro*, or *in vivo* (e.g. in SCID mice). Antibody V regions may be cloned by standard procedures known in the art, or modifications of these procedures. For instance, the V regions may be cloned according to the process described in Example III below.

- 5 Alternatively, chimpanzee H and L chain V region sets with desired binding activity may be screened for as, for example, Fab fragments, Fv fragments, or single-chain Fv, by expression in bacteria, e.g. *E. coli*, or selected through the use of combinatorial libraries expressed in lambda phage, on the surface of bacteriophage, on the surface of bacteria, or screened by display on any
- 10 other biological (e.g. retrovirus or polysome) or non-biological system (Better, M. *et. al.*, Science, 240:1041-1043 (1988); Skerra, A. and Pluckthun, A., Science, 240:1038-1041 (1988); Huse, W.D. *et. al.*, Science 246:1275-1281 (1989); McCafferty, J. *et. al.*, Nature 348:552-554 (1990); Kang, A.S. *et. al.*, Proc. Natl. Acad. Sci. USA 88: 4363-4366 (1991); Fuchs P. *et. al.*, Bio/Technology 9:1369-
- 15 1372 (1991); Francisco, J. *et. al.*, Proc. Natl. Acad. Sci. USA 90:10444-10448 (1993); Mattheakis, L.C. *et. al.*, Proc. Natl. Acad. Sci. USA 91:9022-9026 (1994)). The antibody libraries may be composed of: native V regions from an immunized or unimmunized chimpanzee, synthetic or semi-synthetic V regions, or modified chimpanzee V regions. Examples of the latter include fine-tuning of
- 20 specificity and/or affinity by *in vitro* mutagenesis. The primary basis for selecting the V regions is on the basis of their ligand-binding characteristics.

Chimpanzee H and L chain V region genes may be cloned into a mammalian expression vector containing chimpanzee constant region genes. Introduction of the expression construct(s) into suitable host cells results in

25 production of complete chimpanzee antibodies of a defined specificity. Many eukaryotic expression vectors for antibody have been described that are either stably integrated or exist as extrachromosomal elements, and these are known to those of ordinary skill in the art. The H and L chain transcription units can be introduced into the host cell individually on separate plasmids or together on the

30 same vector.

One example of an expression vector that may be modified to express chimpanzee antibodies is the plasmid, pdHL2 (Figure 3). This vector contains human IgG1 (hu C γ 1) and human kappa constant region (hu C κ) genes in their genomic configuration (Gillies, S.D. *et al.*, J. Immunol. Methods 125:191-202

35 (1989)). Both transcription units contain an upstream immunoglobulin H chain enhancer element (E_H) and mouse metallothionein I promoter. Insertion of V κ region and V_H region cassettes results in expression of complete antibody. Each V gene cassette includes a 5' immunoglobulin leader sequence and a splice donor site

3' of the V gene. The vector also contains a bacterial origin of replication and β -lactamase gene derived from the plasmid pBR322 and an altered mouse dihydrofolate reductase (DHFR) gene under the control of the SV40 early region enhancer, promoter and polyadenylation signal sequences. The DHFR marker gene allows for selection and amplification in mammalian cells with methotrexate.

Antibody expression vectors may be modified to contain any of the constant region genes (in the case of humans: κ , λ , IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE) isolated from any vertebrate species that makes antibodies, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. Similarly, antibody H and L chain V regions may be isolated from any vertebrate species that makes antibodies, including but not limited to: rodent (e.g., mouse, hamster, rat), chicken, rabbit, canine, feline, bovine, equine, porcine, ape (e.g. chimpanzee), and human. Introduction of H and L chain V regions into an antibody expression vector containing H and L chain constant regions derived from the same host species, results in formation of recombinant monoclonal antibody. Thus, monoclonal antibodies of any class or subclass can be produced from any vertebrate species that makes antibodies through the use of recombinant DNA, hybridoma, or a combination of these technologies. The host species chosen is in accordance with the intended purpose of the assay.

Depending on the vector system, many different immortalized cell lines may serve as suitable hosts. These include but are not limited: myeloma (e.g. X63-Ag8.653), hybridoma (Sp2/0-Ag14), lymphoma and Chinese Hamster Ovary (CHO) cells. Expression constructs can be introduced using a variety of techniques, including but not limited to, calcium phosphate precipitation, protoplast fusion, lipofection, retrovirus-derived shuttle vectors, and electroporation. Proper expression leads to secretion of the recombinant chimpanzee antibody into the medium. Alternatively, cells may be lysed and antibody subsequently purified.

Antibody molecules or fragments thereof could also be produced in other systems, including but not limited to: baculovirus, yeast, bacteria such as *E. coli*, and *in vitro* in cell-free systems such as rabbit reticulocyte lysate ((Hasemann, C. and Capra, J.D., Proc. Natl. Acad. Sci. USA 87:3942-3946 (1990); Horwitz, A.H. *et. al.*, Proc. Natl. Acad. Sci. USA 85:8678-8682 (1988); Pluckthun, A. Bio/Technology 9:545-551 (1991); Nicholls *et. al.*, J. Biol. Chem. 268(7):5302-5308 (1993)).

Monoclonal antibodies produced by hybridoma, recombinant DNA, or a combination of these technologies may contain at least two (e.g. IgG) and up to 10

(pentameric IgM) identical binding sites with specificity and affinity to the desired ligand determined by the H and L chain V regions. The complete antibodies contain the entire H and L chain constant regions and thus all of the associated antigenic epitopes. Moreover, the antibodies are monoclonal and thus are of a single-defined specificity and affinity and can be produced in unlimited quantities. One or more of these reagents may be used as calibrators and/or controls in diagnostic assays and kits designed to qualitatively or quantitatively measure levels of specific antibody.

4) A POLYPEPTIDE WHICH BINDS TO A PREDETERMINED LIGAND FUSED TO AN ANTIBODY CONSTANT REGION OF THE DESIRED HOST SPECIES:

A fourth embodiment of the invention relates to a polypeptide capable of specifically binding to a predetermined ligand fused to an antibody constant region or some part of an antibody constant region (one or more constant region domains or one or more individual epitopes derived from the antibody constant region) of the desired host species. This includes any of the following fused to all or part of an antibody constant region of any desired species: (1) short polypeptides, such as one derived from a CDR of an antibody molecule, or those selected on the basis of ligand specificity through the use of, for example, phage display technology; (2) an antibody domain or derivative thereof such as a minibody; (3) Fv fragments; and (4) single-chain Fv fragments (Levi, M. *et. al.*, Proc. Natl. Acad. Sci. USA 90:4374-4378 (1993); Smith, G.P. Science 228:1315-1317 (1985); Martin, F. *et. al.*, EMBO J. 13(22):5303-5309 (1994)). This molecule may consist of one or more polypeptide chains. This embodiment may readily be produced using a wide variety of bacterial vectors well known to the art. Antibody fragments and derivatives thereof may also be produced in other host systems not limited to but including eukaryotic cells (Shu, L. *et. al.*, Proc. Natl. Acad. Sci. USA 90:7995-7999 (1993)).

Reagents derived from this embodiment contain a polypeptide that binds to the chosen ligand with the desired specificity and affinity. This polypeptide is fused to an entire antibody constant region, one or more domains of the constant region, or one or more epitopes of the chosen constant region. The choice of antibody constant region or fragment thereof is dictated by the intended use. These reagents, whether produced in eukaryotic or prokaryotic expression systems, provide a continuous source of a reagent that binds to a predetermined ligand, is "monoclonal" in nature as it is uniform in specificity and affinity, and it contains at least one constant region epitope. One or more of these reagents may be used as

calibrators and/or controls in diagnostic assays and kits designed to qualitatively or quantitatively measure levels of specific antibody.

Any of the reagents described in embodiments 1-4, may be used individually, or alternatively, more than one of these reagents may be used to produce calibrators (standard) and/or controls for an immunoassay. It is envisioned that a calibrator and/or control may be composed of a mixture of two or more reagents: (a) recognizing different epitopes on a given antigen, (b) one or more different epitopes on more than one antigen (e.g. P30 and P66 proteins of *T. gondii*), or one or more epitopes on antigens derived from more than one source (e.g. gp41 antigen of HIV-1 and gp36 antigen from HIV-2, to monitor for antibodies to both HIV-1 and HIV-2 in the same assay). The decision as to how many of these reagents to use to produce a calibrator (standard) and/or control is dependent upon the assay format and desired performance characteristics (e.g. specificity, sensitivity, precision, parallelism), is based on empirical observations and can be determined by methods known to the art.

Use of any of the aforementioned reagents as an alternative to sourcing high titer positive human plasma or serum for production of calibrators (standards) and/or controls in diagnostic assays and kits yields several important advantages:

(1) availability: These reagents can be produced easily and reproducibly in large quantities. The production scale can be readily tailored to demand, providing a renewable in-house supply.

(2) homogeneity: All of these reagents are "monoclonal" in nature in that they are uniform in specificity and affinity. This dramatically reduces lot-to-lot variation. This is in contrast to human plasma pools which vary in antibody concentration, titer of specific antibody, and specificity thereby affecting the immunoassay's performance.

(3) control of epitope specificity: One can readily dictate the specificity and affinity of the reagent. This provides a greater level of control over performance and manufacturability of the immunoassay.

(4) allowance for more complete characterization of the calibrators and controls, thus ensuring reagent quality, and also providing reagents potentially useful for monitoring the coating of antigen on the solid phase, thus reducing lot-to-lot variation in antigen concentration. For some assays, more than one protein antigen is coated on the solid phase. If, for example, the proteins are coated on microparticles, if one was monitoring coating with a polyclonal, it would be necessary to coat them individually and subsequently blend the microparticles. In contrast, with these reagents, beads could be co-coated with all the proteins and the density of each could be determined. These reagents also provide a tool to evaluate

the stability and/or lot-to-lot consistency of specific epitopes on the antigen.

(5) reduced production costs: Unlimited availability coupled with the homogeneous nature of the reagent aids in optimization of purification methodology, both helping to reduce manufacturing, testing and regulatory-related costs, and

(6) safety: Use of biological fluids (e.g. plasma, serum) to manufacture calibrators and controls is potentially biohazardous. Substituting these reagents for biological fluids in the manufacture calibrators and/or controls should significantly reduce the biohazard risk associated with these products.

In addition to use in assays and kits which detect or monitor antibodies to infectious agents (e.g., human immunodeficiency virus-1, human immunodeficiency virus-2, human T-cell leukemia virus-1, human T-cell leukemia virus-2, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis GB virus, respiratory syncytial virus, Rubella virus, *Toxoplasma gondii*, *Trypanosoma cruzi*, *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Helicobacter pylori*, and *Streptococcus pyogenes*), the reagents described in the present invention may also be used to monitor antibody responses to any other antigen. In particular, the reagents may be used in kits and assays which monitor antibodies to autoantigens, allergens, pharmaceuticals, and other environmental antigens. These assays may be designed to monitor/measure all reactive antibody, or alternatively, specific classes or subclasses of reactive antibody. The described agents are useful as calibrators and/or controls for monitoring antibody responses in man as well as any other vertebrate species capable of generating an antibody response and thus have human medical as well as veterinary applications.

The present invention may be illustrated by the use of the following non-limiting examples:

EXAMPLE I

PREPARATION OF CELL LINES

The hybridomas 1-706-139 (IgG2b/ κ) and 5-465-210 (IgG2a/ κ), specific for *Toxoplasma* proteins P66 and P30, respectively, were established by fusion of immunized Swiss Webster spleen cells to the non-secreting hybridoma Sp2/0-Ag14 at Abbott Laboratories (Abbott Park, IL). Hybridomas were passaged in IMDM (550 mg glucose/L) supplemented with 10% fetal bovine serum (FBS), 8 mM L-glutamine, 100U penicillin/ml and 100 μ g/ml streptomycin (complete IMDM). Sp2/0 Ag14 cells (Abbott Laboratories; American Type Culture Collection, Rockville, MD) used for electroporation were passaged in high glucose

35

D-MEM containing L-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES and 10 µg/ml gentamicin (complete D-MEM). Sp2/0 Ag14 cells (Abbott Laboratories) used for transfection by protoplast fusion were passaged in D-MEM (Catalog #11995) supplemented with 20% FBS, 0.8 µg/ml 8-azaguanine (Sigma Chemical Company, St. Louis, MO), 50 U/ml penicillin and 50 µg/ml streptomycin.

Transfectants secreting chimeric antibody were passaged in complete IMDM supplemented with 0.1 µM methotrexate (MTX) purchased from Sigma, Adria Laboratories (Columbus, OH) or Lederele Laboratories (Carolina, Puerto Rico). Unless specified, all tissue culture media and supplements were purchased from BRL Life Technologies (Gaithersburg, MD). Cells were cultured at 37°C in 5% CO₂.

EXAMPLE II

15

CLONING

Primers for cloning and sequencing were purchased from Operon Technologies, Inc (Alameda, CA) unless otherwise specified. Primers used for isolation of immunoglobulin variable (V) regions and for transfer of fragments were HPLC purified. Reagents from Perkin-Elmer GeneAmp Kits (Perkin-Elmer Corporation, Foster City, CA), including AmpliTaq DNA polymerase, were used according to the manufacturer's specifications for polymerase chain reaction (PCR) amplifications. Reverse transcription and PCR reactions were performed on a GeneAmp 9600 thermal cycler (Perkin-Elmer). Restriction enzymes were purchased from BRL Life Technologies or New England BioLabs (Beverly, MA) and digests were performed as recommended by the manufacturer. Unless indicated otherwise, DNA fragments used for cloning were isolated on low-melting point (LMP) agarose (FMC Corporation, Rockland, ME). Briefly, desired fragments were excised from the gel, diced into small pieces and added to 400 µl TE [1 mM ethylenediaminetetraacetic acid (EDTA; pH 8.0; BRL Life Technologies), 10 mM tris(hydroxymethyl)aminomethane-hydrochloride (Tris-HCl; pH 8.0; BRL Life Technologies)] in an eppendorf microfuge tube. The agarose was melted at 68°C and extracted with 800 µl of buffer-saturated phenol (BRL Life Technologies) by vortexing for one minute and centrifugation at 14,000 x g in a microcentrifuge. The aqueous phase was transferred to a new tube and one tenth volume of 10M LiCl₂ (Sigma Chemical Co., St. Louis, MO) was added. The tube was centrifuged as above for 5 minutes. The aqueous phase was transferred to a new tube and precipitated with 2.5 volumes absolute ethanol (-20°C, McCormick Distilling Co., Weston, MO). The DNA was pelleted as above

for 15 minutes and washed 2X with 70% ethanol (-20°C). DNA was resuspended in H₂O or TE. Ligations were performed using a Stratagene DNA ligation kit (Stratagene Cloning Systems, La Jolla, CA) as recommended by the manufacturer. With the exception of protoplast fusion studies, bacterial transformations were performed using MAX EFFICIENCY DH5 α (BRL Life Technologies) competent cells following the manufacturer's protocol. Screening of transformants to identify desired clones was accomplished by restriction digest analysis of miniprep DNA and/or by colony PCR. Miniprep DNA was prepared with the Magic Miniprep Purification System (Promega Corporation, Madison, WI) or with the EasyPrep Plasmid Prep Kit (Pharmacia Biotech, Inc., Piscataway, NJ) following the manufacturer's specifications. For colony PCR screening, individual colonies were picked from transformation plates and transferred into a well in a sterile flat-bottom 96-well plate (Costar, Cambridge, MA) containing 100 μ l sterile H₂O. One-third of the volume was transferred to a second plate and stored at 4°C. The original 96-well plate was microwaved for 5 minutes to disrupt the cells. One μ l volume was then transferred to a PCR tube as template. Nine μ l of a PCR master mix containing 1 μ l 10X PCR buffer, 1 μ l 2 mM dNTPs, 1 μ l (10 pmol) sense primer, 1 μ l (10 pmol) anti-sense primer, 0.08 μ l AmpliTaq DNA polymerase (0.4 units), and 4.2 μ l H₂O was added to the PCR tube. All PCR reagents were purchased from Perkin-Elmer Corporation. Reactions were generally amplified for 20-25 cycles of 94°C for 30 seconds, 50-60°C (depending on primer annealing temperatures) for 30 seconds and 72°C for 60 seconds. Primers were dependent on the insert and cycle conditions were modified based on primer annealing temperatures and the length of the expected product. After cycling, approximately 1/3 of the reaction volume was loaded on an agarose gel for analysis. Colonies containing desired clones were propagated from the transfer plate.

EXAMPLE III

ISOLATION OF VARIABLE REGIONS FROM HYBRIDOMAS, CONSTRUCTION OF EXPRESSION VECTORS AND TRANSFER OF VARIABLE REGIONS INTO EXPRESSION VECTORS

i) ISOLATION OF IMMUNOGLOBULIN VARIABLE REGIONS:

A Pharmacia QuickPrep mRNA Purification Kit was used according to the manufacturer's specifications to isolate mRNA from 1 X 10⁷ hybridoma cells. First-strand complementary DNA (cDNA) synthesis and PCR amplification were performed with a Perkin Elmer GeneAmp RNA PCR Kit. For specific cDNA synthesis of heavy (H) chain V regions, 90 ng of purified hybridoma mRNA and

37

10 pmol of the primer M-IgG2b (Table 1) or M-IgG2a, both containing a *Bgl* II site were used for 1-706-139 and 5-465-210, respectively. Specific cDNA priming of both kappa (κ) light chain variable (V) regions was carried out with the primer MK-REV containing a *Bgl* II site. Reverse transcription reactions were incubated at 42°C for 60 minutes then at 99°C for 5 minutes. PCR reactions (100 μ l volume; 50 pmol of each primer) were set up according to the manufacturer's specifications. For 1-706-139 V_H region amplification, sense primer MHV-9 and the primer M-IgG2b were used. The 1-706-139 V κ region was amplified with MKV-1 (sense) and MK-REV primers. For 5-465-210 V_H region amplification, primers MHV-7 (sense) and M-IgG2a were used. Amplification of the 5-465-210 V κ region was performed with MKV-2 (sense) and MK-REV primers. All sense primers contained a *Sal* I site. Amplifications consisted of 30 cycles of 94°C for 30 seconds, 52°C for 30 seconds and 72°C for 60 seconds. PCR-derived products were isolated by the Promega Magic PCR Preps DNA Purification System (Madison, WI). V_H and V κ fragments were digested with *Sal* I and *Bgl* II and ligated into *Sal* I and *Bam* HI digested pUC18 (BRL Life Technologies). Plasmids pJH6-20-94A1 and pJH6-14-94A5 contain V_H and V κ regions, respectively, cloned from hybridoma 1-706-139. Plasmids pJH6-30-94A1 and pJH7-31-94D3 contain V_H and V κ regions, respectively, isolated from hybridoma 5-465-210.

Table 1

Primers used for isolation of hybridoma V regions

M-IgG2b	5'-d[ATTCGGATAGATCTAGTGGATAGACTGATGG]3' (SEQ ID NO:9)
M-IgG2a	5'd[ATTCGGATAGATCTAGTGGATAGACCGATGG]3' (SEQ ID NO: 10)
MK-REV	5'd[ATTCGGATAGATCTTGGATGGTGGGAAGATG]3' (SEQ ID NO:11)
MHV-9	5'd[ACACTAGTCGACATGGMTTGGGTGTGGAMCTTGCTATT CCTG]3' (SEQ ID NO:12)
MKV-1	5'd[ACACTAGTCGACATGAAGTTGCCTGTTAGGCTGTTGGTG CTG]3' (SEQ ID NO:13)

38
Table 1 (continued)

MHV-7	5'd[ACACTAGTCGACATGGGRATGGAGCKGGRTCTTTMTCTT] 3' (SEQ ID NO:14)
MKV-2	5'd[ACACTAGTCGACATGGAGWCAGACACACTCCTGYTATG GGT]3' (SEQ ID NO:15)

ii) HUMAN IgM EXPRESSION VECTOR CONSTRUCTION:

5 The immunoglobulin expression vector pdHL2 (Figure 3; Gillies, S.D. *et al.*, (1989) J. Immunol. Methods 125:191-202) was modified for expression of human IgM (Figure 4) by replacing the human IgG1 constant region (C_γ1) with a genomic clone of the human IgM constant region (C_μ). The first step was to introduce a *Spe* I restriction site into the *Sac* II site 31 bp upstream of the first exon of C_γ1. The coding strand oligonucleotide Spe-1, 5'd[GGAAGTGGAGC]3' (SEQ ID NO:18), was annealed to the oligonucleotide Spe-2, 5'd[TCCACTAGTTCCGC]3' (leaving *Sac* II overhangs) (SEQ ID NO:19), and ligated into *Sac* II digested pdHL2, yielding the vector pAG/*Spe*I.

15 The C_γ1 gene in pAG/*Spe*I is flanked by *Spe* I and *Eag* I (located 7 bp downstream of the termination codon) sites and was removed by a double digestion with these enzymes. A fragment containing a genomic clone of the secretory portion of C_μ was generated by PCR amplification using 1 ng of the vector H+L cassette #1 (8/89) Hyland (Abbott Biotech) as template and 50 pmol of the primers 5'huM-B (Table 2), containing a *Spe* I site and 3'-huMEag, containing an *Eag* I site. Amplification consisted of 24 cycles of 94°C for 30 seconds, 63°C for 30 seconds, and 72°C for 90 seconds. The 1880 bp IgM C_μ product (position 219 through 2099 in Dorai, H. and Gillies, S.D., Nucleic Acids Research 17:6412 (1989)) was gel-isolated, double digested with *Spe* I and *Eag* I, and cloned into pAG/*Spe*I (replacing the IgG1 gene) to generate pAG/*Spe*I/huM.

25 Plasmids pAG/huM/αtox and pAG/huM/αtox 5-465 were constructed by transfer of the 1-706-139 and 5-465-210 V region sets, respectively, into pAG/*Spe*I/huM (see section below). Preliminary studies with these constructs revealed low levels of recombinant IgM expression so the constructs were further modified. A genomic clone of the secretory portion of the C_μ gene that contains native IgM poly A signal sequences was PCR amplified, under the conditions outlined above, using 1 ng of plasmid pN-χ-μTNP DNA (obtained from Dr. Marc Shulman, University of Toronto, Toronto, Ontario; Boulianne, G.L., *et al.*,

30

Nature 312:643-646 (1984)) as template and 50 pmol each of the primers 5'huM-B and 3'amp-hoM (containing an *EcoR* V site). Gel-isolated C μ (position 128 through 2278 in Word, C.J., *et. al.*, International Immunology 1:296-309 (1989)) PCR product was ligated into the vector, pGEM-T (Promega Corporation, Madison, WI), following the manufacturer's recommended conditions. A clone containing the C μ insert was identified and designated pGEM/IgM. The entire IgM insert was sequenced to verify its integrity.

Plasmid pGEM/IgM was modified by extending the native 5' intron sequences upstream of C μ exon 1. The intron fragment (5' end at position 17 in Word, C.J. *et. al.*, International Immunology 1:296-309 (1989)) was PCR amplified using 1 ng pN- χ - μ TNP plasmid DNA as template and 50 pmol each of the primers 5-SPL/Spe containing a *Spe* I site and 3-SPL (both synthesized at Abbott). After 24 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 45 seconds, the intron fragment was phenol/chloroform extracted and precipitated. Both intron product and pGEM/IgM vector were digested with *Spe* I and *Bsu* 36 I (New England Biolabs), gel isolated, and ligated to generate the human C μ gene construct pJH2-14-95A3. The intron insert was characterized by sequencing.

Plasmid pAG/huM/ α tox 5-465 was modified by replacing its C μ gene segment with the human C μ gene segment containing native 5' intron and poly A signal sequences, present in pJH2-14-95A3 (referred to as complete C μ). Plasmid pAG/huM/ α tox 5-465 was double digested with *Spe* I and *Pvu* II (downstream of C γ 1 poly A addition site; position 2137 in GenBank accession # Z17370) and the vector backbone was gel isolated. The complete C μ gene was released from pJH2-14-95A3 by digestion with *Spe* I and *Eco* RV. Ligation of the gel isolated fragments resulted in the plasmid pJH2-24-95B1 (Figure 3). This expression vector contains murine V H and V κ genes isolated from hybridoma, 5-465-210, and genomic clones of human C μ and C κ genes.

A second version of this expression vector, pJH3-19-95A, containing V κ and V H genes cloned from hybridoma, 1-706-139, was constructed by replacing the *Xba* I-*Hind* III fragment in pJH2-24-95B1 (containing V κ 5-465-210, the kappa constant region and V H 5-465-210) with the analogous *Xba* I-*Hind* III fragment isolated from the plasmid pAG/huM/ α tox (Figure 5). The final IgM expression vectors pJH2-24-95B1 and pJH3-19-95A were both introduced into *E. coli* C600R⁻ (American Type Culture Collection) in preparation for transfection by protoplast fusion.

iii) TRANSFER OF IMMUNOGLOBULIN V REGIONS INTO THE IgM
EXPRESSION VECTOR:

The V κ and V $_H$ regions cloned from the hybridomas were introduced as cassettes into the immunoglobulin expression vector pAG/SpeI/huM containing transcription units for the human C κ and human C μ . Proper expression of the V κ and V $_H$ regions requires the addition of part of the 5' leader sequences and 3' splice donor junctions. These regions were incorporated into primers (Table 2) used for sequential PCR-mediated transfer of V κ and V $_H$ regions into the expression vector. For transfer of the 1-706-139 V κ gene, the 5' (leader) primer VK1-706-5', containing an *Xba* I site, and the 3' primer VK1-706-3' containing a splice junction and *Bam* HI site were used. For 1-706-139 V $_H$ region amplification, the 5' (leader) primer VH1-706-5' containing a *Xho* I site and the 3' primer VH1-706-3' containing a *Hind* III site were used. For 5-465-210 V κ gene transfer, the 5' (leader) primer VK5-465-5' containing an *Xba* I site and the 3' primer VK5-465-3' containing a *Bam* HI site were used. For 5-465-210 V $_H$ gene transfer, the 5' (leader) primer VH5-465-5' with a *Xho* I site and the 3' primer, VH5-465-3', containing a *Hind* III site were used. The 100 μ l volume reactions included 50 pmol of each primer and 1 ng of plasmid template [pJH6-14-94A5 (1-706-139 V κ); pJH6-20-94A1 (1-706-139 V $_H$); pJH7-31-94D3 (5-465-210 V κ); or pJH6-30-94A1 (5-465-210 V $_H$)]. Amplification consisted of 22 cycles of 94°C for 30 seconds, 62°C for 30 seconds and 72°C for 60 seconds. PCR-derived V κ products were digested with *Xba* I and *Bam* HI and cloned into vector (pAG/SpeI/huM) digested with *Xba* I and *Bam* HI. Subsequently, the V $_H$ product was introduced into the V κ containing vector using *Xho* I and *Hind* III. The integrity of the V κ and V $_H$ inserts was established by sequence analysis. The resulting expression vectors, pAG/huM/ α tox and pAG/huM/tox 5-465, contain the 1-706-139 and 5-465-210 V region sets (V κ and V $_H$), respectively.

Table 2
Primers for construction of IgM expression vectors

5'huM-B	5'd[TGACTGTAAGTCTGCGGGTCCTCAGGGAGTGCATC CGCCCCAACCCCTTTCCCCCTC]3' (SEQ ID NO:16)
3'-huMEag	5'd[TGATCTAGCGGCCGTCGCACTCAGTAGCAGGTGCCAGC TGTGTCGGAC]3' (SEQ ID NO: 56)
3'amp-hoM	5'd[CTGATCGAGATATCAAGCCACTGAGGCACGCAGGTGGG TG]3' (SEQ ID NO: 57)
5-SPL/Spe	5'd[TCAGGTGACTGAACTAGTCCTTGGTGGGGCAGCCACAG CG]3' (SEQ ID NO: 58)
3-SPL	5'd[CGACGGGGAATTCTCACAGGAGAC]3' (SEQ ID NO:17)
VK1-706-5'	5'd[TCACGAAGTCTAGACCTCAAATGAAGTTGCCTGTTAGGC TGTTGGTG]3' (SEQ ID NO: 59)
VK1-706-3'	5'd[GAATCTATGGATCCTGACACACTTACGTTTGATTTCAGC TTGGTGCCTCC]3' (SEQ ID NO: 60)
VH1-706-5'	5'd[ACACTATACTCGAGACATCATGGCTTGGGTGTGGACCTT GCTA]3' (SEQ ID NO: 61)
VH1-706-3'	5'd[TTGAGATCAAGCTTGACACACTTACCTGAGGAGACGGTG ACTGAGGTTCC]3' (SEQ ID NO: 62)
VK5-465-5'	5'd[TCACGAAGTCTAGAGCTCTCAGAGATGGAGTCAGACAC ACTCCTGCTA]3' (SEQ ID NO: 63)
VK5-465-3'	5'd[GAATCTATGGATCCTGACACACTTACGTTTTATTTCAGC TTGGTCCCCG]3' (SEQ ID NO: 64)

42

Table 2 (continued)

VH5-465-5'	5'd[ACACTATACTCGAGACTCCAACCATGGGATGGAGCTGG ATCTTTCTC]3' (SEQ ID NO: 65)
VH5-465-3'	5'd[TTCAGATCAAGCTTGACACACTTACCTGAGGAGACTGTG AGAGGGGTG]3' (SEQ ID NO: 66)

iv) TRANSFER OF MURINE V REGION SETS INTO A HUMAN IgG1
EXPRESSION VECTOR:

- 5 To generate a construct for expression of the functional V_K and V_H
regions cloned from the hybridoma 1-706-139 as IgG1, the *Xba* I-*Hind* III
fragment encompassing both of these regions was excised from pAG/huM/ α tox
and introduced into *Xba* I and *Hind* III digested pdHL2, yielding the expression
construct designated pJH9-14-94/4.1. The same procedure was used to transfer
10 the V_K and V_H gene set isolated from hybridoma 5-465-210 from the plasmid
pAG/huM/ α tox 5-465 into pdHL2 to generate the expression construct, pdHL-
2/5-465 (clone 1).

EXAMPLE IV

15 SEQUENCING OF VARIABLE REGIONS IN EXPRESSION VECTORS

- Plasmid template for sequencing was prepared with Magic Miniprep or
Maxiprep DNA Purification Systems (Promega), the EasyPrep Plasmid Prep Kit
(Pharmacia), or by CsCl banding (Sambrook J. *et. al.*, Molecular Cloning, 2nd
edition, Cold Spring Harbor, New York, Cold Spring Harbor Press (1989)). The
20 manufacturers recommended procedures were followed for preparation of
plasmids with the kits. Nucleotide sequences were determined manually by
Sequenase version 1.0 with a Sequenase 7-deaza-dGTP DNA Sequencing Kit
(Amersham Life Science, Inc., Arlington Heights, IL) or by automated sequencing
using the Pharmacia AutoRead Sequencing Kit and ALF DNA Sequencer. The
25 vector primers (Table 3) ALF M13 Universal (Pharmacia) and ALF M13 Reverse
(Pharmacia) were used for sequencing V_H and V_K inserts. Multiple clones of
PCR-generated V_H and V_K regions were sequenced to monitor for AmpliTaq DNA
polymerase-induced errors.

- 30 Primers used for sequencing of V_H and V_K fragments cloned into the
mammalian expression vectors included the primers: pdHL2-4F, pdHL2-7F,
pdHL2-43, pdHL2-44, pdHL2-52 and pdHL2-53. In addition, T1706H-A and
T1706H-B, for 1-706-139 V_H; T1706K-A and T1706K-B for 1-706-139 V_K;

43

T5465H-A, T5465H-B, and T5465H-C for 5-465-210 V_H; and T5465K-A, T5465K-B, and T5465K-C for the V_K region cloned from 5-465-210.

Primers used for sequencing of the human IgM genomic clone are listed in Table 4.

5

Table 3

Primers for sequencing variable region inserts in the expression vectors

ALF M13 Universal	5'-fluorescein-d[GTAAAACGACGGCCAGT]3' (SEQ ID NO: 67)
ALF M13 Reverse	5'-fluorescein-d[CAGGAAACAGCTATGAC]3' (SEQ ID NO: 68)
pdHL2-4F	5'-fluorescein-d[ACGTCATCCGACCCCCTCAG]3' (SEQ ID NO: 20)
pdHL2-7F	5'-fluorescein-d[CTGCCCCAAAGCCAAGGTCA]3' (SEQ ID NO: 21)
pdHL2-43	5'd[CTCCAGCTTCACCAGATCCCTCGAC]3' (SEQ ID NO:22)
pdHL2-44	5'[CTCCAGCTTCACCAGATCCCTCGAG]3' (SEQ ID NO:23)
pdHL2-52	5'd[GCCACCTGCCTCACCTTAG]3' (SEQ ID NO:24)
pdHL2-53 (Abbott Labs)	5'd[AGAATGGCCACGTCATCCG]3' (SEQ ID NO:25)
T1706H-A	5'd[TCCAATGCACTGGGTGAAGC]3' (SEQ ID NO:26)
T1706H-B	5'd[GCAAACCGTCCCTTGAAGTC]3' (SEQ ID NO:27)
T1706K-A	5'd[ATTTACATTGGTATCTGCAG]3' (SEQ ID NO:28)
T1706K-B	5'd[CCAGAAAATCGGTTGGAAAC]3' (SEQ ID NO:29)
T5465H-A	5'd[CGAGACTCCAACCATGGGAT]3' (SEQ ID NO:30)
T5465H-B	5'd[TGATAGAGTGGGTGACACAG]3' (SEQ ID NO:31)

44

Table 3 (continued)

T5465H-C	5'd[GCCCTGCCCTTGAATTTCTC]3' (SEQ ID NO:32)
T5465K-A	5'd[TAGAGCTCTCAGAGATGGAG]3' (SEQ ID NO:33)
T5465K-B	5'd[CTATGCTGCATCCAACCTAG]3' (SEQ ID NO:34)
T5465K-C	5'd[GATGAATGTTGAGGGTGAAG]3' (SEQ ID NO:35)

5

Table 4

Sequencing primers for genomic clone of the IgM constant region

HMC-1	5'd[ATACAAGAACAACCTCTGACA]3' (SEQ ID NO:36)
HMC-2	5'd[GTCTTCGTCCCACCCCGCG]3' (SEQ ID NO:37)
HMC-3	5'd[CTCCATGTGTGTCCCCGGTG]3' (SEQ ID NO:38)
HMC-4	5'd[ATCCTTTGCCAGCATCTTCC]3' (SEQ ID NO:39)
HMC-5	5'd[ACTCTTGCCCCTCTTCCTGC]3' (SEQ ID NO:40)
HMC-6	5'd[GACCAGCGCCCCAATGCCTG]3' (SEQ ID NO:41)
HMC-7B	5'd[TTTGCATGCACACACAGAGC]3' (SEQ ID NO:42)
HMC-8	5'd[GCATCCACTGCACGAAGACG]3' (SEQ ID NO:43)
HMC-9	5'd[AGGGCAGGTCTGTGTGGGTC]3' (SEQ ID NO:44)
HMC-10	5'd[CATGGTTCCCACCCAAAGAG]3' (SEQ ID NO:45)
HMC-11	5'd[ACTCTTTGGCCTCAGCCTGC]3' (SEQ ID NO:46)

45
Table 4 (continued)

HMC-12	5'd[GCACACCACGTGTTCGTCTG]3' (SEQ ID NO:47)
HMC-13	5'd[GTGCATGCAAACCTAACCGTG]3' (SEQ ID NO:48)
45403 (igm1) Abbott Laboratories	5'd[GCTCCTCCCATATGGTCGAC]3' (SEQ ID NO:49)
45404 (igm2) Abbott Laboratories	5'd[CAGGCCCGATGTCTACTTGC]3' (SEQ ID NO:50)
45405 (igm3) Abbott Laboratories	5'd[CTCATGGGCCACCACGCAGG]3' (SEQ ID NO:51)
45406 (igm4) Abbott Laboratories	5'd[CTGCGAGGATGACTGGAATT]3' (SEQ ID NO:52)
45407 (igm5) Abbott Laboratories	5'd[GCTGGTCACATACTTCTCCG]3' (SEQ ID NO:53)
pdHL2-46	5'd[CGGGAGCTGCATGTGTCAG]3' (SEQ ID NO:54)
pdHL2-54 Abbott Laboratories	5'd[CAGACACTGGACGCTGAACC]3' (SEQ ID NO:55)
Reverse M13 <i>lac Z</i> primer (Perkin-Elmer)	5'd[GAGCGGATAACAATTTCACACAG G]3' (SEQ ID NO:69)
-21 (M13) primer (Applied Biosystems, Inc)	5'd[TGTAAAACGACGGCCAGT]3' (SEQ ID NO: 70)

EXAMPLE V

TRANSFECTION OF EXPRESSION VECTORS INTO HOST CELLS

- 5 Plasmids used for electroporation were purified by CsCl banding
(Sambrook J. *et. al.*, Molecular Cloning, 2nd edition, Cold Spring Harbor, New
York, Cold Spring Harbor Press (1989)). To transfect by electroporation, Sp2/0-
Ag14 cells in log-phase growth were harvested and washed twice in 10 ml
Dulbeccos phosphate buffered saline (D-PBS, BRL Life Technologies), and
10 resuspended in D-PBS to a concentration of 1×10^7 cells/ml. Ten μ g of *Sal* I
linearized plasmid DNA was added to 1×10^7 Sp2/0-Ag14 cells in a 0.4 cm gap
Bio-Rad (Melville, NY) electroporation cuvette in a total of 1 ml D-PBS. DNA and
cells were incubated on ice 10 minutes. The cuvette was placed into the chamber
of a Bio Rad Gene Pulser set at 0.18 kv and 960 μ F capacitance. Current was

applied and cuvette was mixed to eliminate the pH gradient. Cells were placed on ice for 5 minutes prior to plating. Cells were transferred to 19 ml compete D-MEM media and gently mixed. 100 μ l of cell suspension was added to each well of two 96-well tissue culture clusters (flat-bottom; Costar) and incubated at 37°C in 5% CO₂. After 24 hours, 100 μ l of complete D-MEM supplemented with 0.1 μ M MTX (Sigma), was added to each well, and plates were incubated as above. After 48 hours, 100 μ l media was removed from each well, and 100 μ l of compete D-MEM with 0.1 μ M MTX was added back. This process was repeated after 48 hours. Plates were subsequently incubated for 10 to 21 days until colonies began to appear. Supernatants were harvested from wells containing MTX-resistant colonies and assayed by ELISA (see below) for the presence of chimeric antibody.

A second method used to establish Sp2/0-Ag14 transfectants was a modified version of the protoplast fusion technique (Sandri-Golden, R.M. *et. al.*, Molecular and Cellular Biology 1:743-752 (1981); Gillies, S.D. *et. al.*, Cell 33:717-728 (1983)). Plasmids were propagated in *E. coli* C600R⁻ to generate protoplasts. Bacteria were grown at 37°C with vigorous aeration in 50 ml of medium containing 10 mg/ml M9 salts (BRL Life Technologies), 0.8% Casamino acids (Difco, Detroit, MI), 0.5% glucose (BRL Life Technologies), 0.1 mM CaCl₂ (Sigma), 1 mM MgSO₄ (Sigma), and 50 μ g/ml ampicillin (Sigma) to an absorbance at 600nm of 0.5-0.6. Chloramphenicol (Sigma) was added to 200 μ g/ml, and the culture incubated as above for an additional 18-22 hours. Cells were pelleted at 1100 x g for 12 minutes at 4°C and resuspended in 2.5 ml of 20% sucrose (Sigma) in 0.05 M Tris-HCl, pH 8.0 (BRL Life Technologies) at 4°C. A solution of 5 mg/ml lysozyme (Pharmacia) in 0.25 M Tris-HCl (pH 8.0) was added and the mixture placed on ice. After a 5 minute incubation, 1.0 ml of 0.25 M EDTA (pH 8.0; BRL Life Technologies) was added and the mixture held on ice for an additional 5 minutes. One ml of 0.05 M Tris-HCl (pH 8.0) was then added slowly. The suspension was incubated at 37°C for 10 minutes. Subsequently, 20 ml of D-MEM (Catalog #11995, BRL Life Technologies) supplemented with 10 mM MgCl₂ (Sigma) and 10% sucrose (Sigma) at room temperature was used to slowly dilute the protoplast solution. This mixture was held at room temperature for 2.5 hours. Approximately 5X10⁶ Sp2/0 Ag14 cells harvested in log-phase growth were pelleted at 350 x g for 5 minutes. Cells were gently resuspended in the protoplast suspension. This suspension was transferred to a 60 mm dish and centrifuged at 650 x g for 8 minutes. The supernatant was aspirated and 1.5 ml of 50% w/v PEG (Sigma Hybri Max) in PBS prewarmed to 37°C was added. The dish was centrifuged at 110 x g until 90 seconds had elapsed from the point of PEG addition. Cells were gently resuspended by pipetting in two 5 ml and one 10

47

ml volumes of prewarmed wash solution (D-MEM supplemented with 1% FBS, 50 U/ml penicillin and 50 µg/ml streptomycin) which were added to a 50 ml centrifuge tube containing 15 ml of the wash solution. After centrifugation at 225 x g for 7.5 minutes, cells were resuspended in plating medium (D-MEM supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin and 100 µg/ml kanamycin (Sigma) and plated in one 96-well dish and incubated at 37°C. After 24 hours (day 1), selective medium (D-MEM supplemented with 10% FBS and 0.1 µM MTX) was added. On day 5, 50 µl of the selective medium was added per well. After two days, 100 µl/well was removed and 100 µl of fresh selective medium added per well. MTX-resistant colonies were tested for secretion of chimeric antibody by ELISA assay.

EXAMPLE VI

ASSAYS FOR THE DETERMINATION OF CHIMERIC ANTIBODY PRODUCTION BY TRANSFECTANTS

Transfectants were assayed by ELISA for production of chimeric IgG1. EIA plates (96-well, Nunc Immulon, Naperville, IL) were coated with 100 µl mouse anti-human IgG (H + L chain; Jackson Immuno Research, West Grove, PA) at 1.5 µg/ml and incubated at 37°C for 1 hour. Plates were washed 4 times in 1X Dulbecco's phosphate-buffered saline without Ca or Mg (D-PBS; BRL Life Technologies). Wells were blocked with 200 µl of 2.0% non-fat dry milk (Carnation Company, Los Angeles, CA) in 1X D-PBS for 1 hour at 37°C. Plates were washed as above. Purified human IgG (Jackson Immuno Research) or purified chimeric IgG1 antibody (Abbott Laboratories) diluted in 1X D-PBS with 2% nonfat dry milk and 0.05% Tween-20 (Bio Rad) were used as a standard. Standards and culture supernatants were added to the plate in duplicate, 100 µl/well, incubated at 37°C for 1 hour, then washed 4 times in D-PBS with 0.1% Tween-20. To each well, 100 µl of mouse anti-human IgG (H + L chain) conjugated to horse radish peroxidase (Jackson Immuno Research) at 0.45 µg/ml was added and incubated for 1 hour at 37°C. Plates were washed as above. The assay was developed using an OPD reagent kit (Abbott Laboratories) and read on a Bio-Rad 96-well plate reader.

The ELISA was modified to assay for production of chimeric IgM. Plates were coated with 0.36 µg/ml goat anti-human IgM (Fc5µ-specific, Jackson ImmunoResearch) in D-PBS. ChromPure human IgM (myeloma, whole molecule, Jackson ImmunoResearch) was used as a standard. Peroxidase-labeled goat anti-human IgM (Fc5µ, Jackson ImmunoResearch) at 0.8 µg/ml was used as the enzyme antibody conjugate.

Antibody concentrations were determined by Radial Immunodiffusion (RID). Seven-fourteen day old cell culture supernatants were vortexed and then 5 or 10 μ l samples for IgG and IgM, respectively, were applied to each well of human IgG or human IgM RID plates (The Binding Site, San Diego, CA). A set of standards (25, 50, 75, 100 and 150 μ g/ml) were run on each plate. The standard for chimeric IgG1 was protein A-purified anti-P66 IgG1, and the IgM standard was ChromPure human IgM (Jackson ImmunoResearch). The plates were incubated inverted at 35-37°C for 16-22 hours. The diameter of each ring was determined in millimeters using a RID Electronic plate reader (The Binding Site) which was calibrated with the calibration plate provided by the Binding Site.

EXAMPLE VII

PURIFICATION OF RECOMBINANT ANTIBODY

To purify chimeric IgG1 antibodies, culture supernatants were initially dialyzed overnight against 0.1 M sodium phosphate (pH 8.2) and with 0.1% sodium azide, then filtered through a 0.2 μ m filter. The preparation was then passed through a column containing PerSeptive Biosystems Poros 50A resin (Cambridge, MA) using a Bio Rad low-pressure chromatography system at 250-500 cm/hour. Antibody was eluted with 0.1M citrate, 0.15 M NaCl pH3.0 and pooled fractions were dialyzed against PBS (10 mM sodium phosphate, 150 mM NaCl) pH 7.2 .

To purify chimeric IgM antibodies, culture supernatants were diluted 1:1 with H₂O and the preparation was loaded on a column containing 175 ml DEAE FastFlow resin (Pharmacia) equilibrated with PBS at a flow rate of 10 ml/minute. Antibody was eluted with 10 mM sodium phosphate, 300 mM NaCl at pH 7.2.

EXAMPLE VIII

TOXOPLASMA GONDII ASSAY

30 i) Hybridoma Selection:

To establish the feasibility of using chimeric mouse-human monoclonal antibodies as controls and calibrators in immunoassays designed to measure human antibodies specific for an immunizing agent, a *T. gondii* assay was selected as a model system and represents one embodiment of the invention.

35 A panel of monoclonal antibodies was established from mice immunized with *T. gondii*. This panel was specific for many different *T. gondii* antigens. The first step was to identify monoclonal antibodies with desired characteristics of affinity and specificity. Monoclonal antibodies reacting to P66 and P30, two

diagnostically useful proteins of *T. gondii*, were chosen. The monoclonal antibodies were screened on the basis of their ability to inhibit the binding of human positive plasma to *T. gondii* in an effort to identify those reacting to immunodominant epitopes. Based on this analysis (data not shown), two
5 monoclonal antibodies were selected, 1-706-139 and 5-465-210, specific for P66 and P30 of *T. gondii*, respectively.

ii) Cloning and Sequencing of Antibody Variable Regions:

Hybridoma cells producing the monoclonal antibodies served as the source
10 of mRNA for preparation of cDNA. To facilitate cloning of expressed H and L chain V regions, specific cDNA synthesis was primed with oligonucleotides hybridizing to the 5' end of the constant regions. For V_H cDNA, IgG2b or IgG2a-specific primers were used with mRNA isolated from the hybridomas 1-706-139 and 5-465-210, respectively. Both V_L cDNAs were initiated with a murine κ
15 constant region primer. PCR amplification of the antibody V regions was performed with degenerate primers annealing to conserved V_H and V κ gene leader sequences (Jones, S.T. and Bendig, M.M., Bio/Technology 9:88-89 (1991)) in conjunction with the constant region primers. The amplification products were cloned into pUC18 and sequenced. Multiple clones of each PCR-product were
20 sequenced to resolve any Taq polymerase induced errors.

The V_H and V_L cDNA sequences isolated from hybridoma 5-465-210 are shown in Figures 6 and 7 in their final cassette format. The V_H cDNA encodes a complete V region gene consisting of a leader sequence, V_H gene, and a D region rearranged to J_H2. The V_H gene appears to be a member of murine subgroup IIB
25 (Kabat E.A. *et. al.*, Sequences of Proteins of Immunological Interest, 5th edition, U.S. Department of Health and Human Services, Bethesda, MD (1991)). The degenerate leader-region amplification primer extended to nucleotide 41, so the authentic cDNA sequence begins at position 42 and extends to position 430. The V_L cDNA consists of a leader sequence and V κ gene rearranged to a J κ -minigene.
30 The V κ gene is apparently a member of the V κ III subgroup. The J κ segment contains four mismatches from the published germline sequence of the J κ 2-minigene isolated from the BALB/c mouse strain (Sakano, H. *et. al.*, Nature 280:288-294 (1979); Max, E.E. *et. al.*, Pro. Nat'l Acad. Sci. USA 76:3450-3454 (1979); Max, E.E. *et. al.*, J. Biol. Chem. 256:5116-5120 (1981)). These
35 mismatches may reflect somatic mutations or represent differences in the germline sequence as Swiss Webster mice were utilized in this study. The degenerate leader-region primer used to isolate the expressed V κ region extended to nucleotide 45, thus authentic cDNA sequence extends from position 46 through position 409.

The V_H cDNA sequence cloned from hybridoma 1-706-139 is illustrated in Figure 8. The degenerate leader-region PCR primer ends at residue 41, so authentic cDNA sequence extends from position 42 through 434. The expressed V_H region includes leader sequences, a V_H gene, apparently from subgroup IIA (Kabat E.A. *et. al.*, Sequences of Proteins of Immunological Interest, 5th edition, U.S. Department of Health and Human Services, Bethesda, MD (1991)), a D segment and J_H4-minigene. The exact boundary between the D and J_H4 segments could not be determined. The sequence of the V_L cDNA isolated from hybridoma 1-706-139 is given in Figure 9. The primer used to amplify the V_L fragment ended at nucleotide 42 so the actual cDNA sequence extends from 43 through 405. The V_L cDNA is comprised of a leader sequence and a V_κ gene, likely from subgroup V_κII, rearranged to J_κ1.

iii) Expression Vector Construction:

The objective of this study was to produce chimeric mouse-human antibodies containing V regions derived from the murine hybridomas and human constant regions. To facilitate expression, the V_H and V_L chain cDNAs were modified so as to contain a complete 5' leader sequence, 3' splice donor site, and flanking cloning sites. The V_H and V_L transfer cassettes (Figures 6-9) were generated by PCR amplification with synthetic oligonucleotides containing the required elements at their 5' ends and 3' sequences specific for each V region. An appropriate leader sequence was determined for each V gene based on its homology to other V region sequences in the database that included their native leader sequence. In all cases, the leader-V region intron has been eliminated. A splice donor site was recreated in each V region cassette at the 3' end of the VDJ or VJ exons of the cDNAs by incorporating a synthetic intron fragment. The splice site junction between the V and constant regions serves to maintain the integrity of both coding sequences. Moreover, this enables the V cassettes to be placed upstream of any constant region, adding to the versatility of the system.

The modified cDNAs were then introduced into mammalian expression vectors downstream of regulatory sequences that provide for high level expression. The vector, pdHL2 (Figure 3) contains transcriptional units for antibody H and L chain genes both under the control of a mouse immunoglobulin H-chain enhancer and metallothionein I promoter. Plasmid pdHL2 contains human kappa (C_κ) and IgG1 (C_γ1) constant region genes in their genomic configuration (Gillies *et. al.*, J. of Immunol. Methods 125:191-202 (1989)). Introduction of the murine V_H and V_κ region cassettes results in expression of mouse-human chimeric antibody. In addition, pdHL2 contains a mutated DHFR

gene allowing for selection of transfectants based on MTX resistance (Gillies *et al.*, J. of Immunol. Methods 125:191-202 (1989)). The 5-465-210 V_H and V_K cDNA cassettes were introduced into pdHL2, generating the expression vector pdHL-2/5-465. This vector encodes chimeric IgG1 antibody specific for P30.
5 Similarly, the 1-706-139 V_H and V_K region cassettes were cloned into pdHL2 yielding pJH9-14-94/4.1, encoding chimeric IgG1 antibody specific for P66 antigen.

To produce chimeric mouse-human IgM class antibodies, pdHL2 was modified by replacement of the C_γ1 gene with a genomic clone of the human IgM (C_μ) gene (Figure 4). The expression vector containing C_μ was designated
10 pAG/SpeI/huM. In this first generation IgM vector, 3' untranslated and poly A signal sequences originally present downstream of C_γ1 were maintained. Chimeric IgM expression constructs were generated by sequential transfer of the V_K and V_H cassettes into this vector. In preliminary experiments with these
15 constructs, all transfectants had very low secretion levels (<1μg/ml) of chimeric IgM (data not shown).

In an effort to enhance chimeric IgM production, new constructs were generated in which the C_μ gene and the poly A signal sequences (originally downstream of C_γ1) were replaced with a genomic clone of the secretory portion
20 of human C_μ including native 5' intron (contains splice acceptor site), 3' untranslated, and poly A signal sequences (Figure 4). Sequence analysis of the C_μ clone revealed only a single base change relative to the published germline sequence (Word C.J. *et al.*, International Immunology 1:296-309 (1989)), the insertion of a T between residues 1583 and 1584 in the C_μ3-C_μ4 intron. This
25 alteration would not be expected to effect expression of the C_μ gene. The IgM expression construct containing the 5-465-210 V_H and V_K regions was designated pJH2-24-95B1 (Figure 3). Replacement of the 5-465-210 V region set with a *Xba*I-*Hind* III fragment containing the 1-706-139 V_H and V_K cassettes (Figure 5), yielded plasmid pJH3-19-95A, encoding chimeric IgM specific for P66.

iv) Expression of Chimeric Antibodies:

The chimeric antibody expression constructs were transfected into the non-producing Sp2/0-Ag14 cells. Both chimeric IgG1 constructs were introduced by electroporation whereas the chimeric IgM constructs were transfected by protoplast fusion. Transfectants were selected in the presence of 0.1 μ M MTX. Multiple MTX-resistant colonies from each transfection were screened for production of chimeric antibody using an anti-human antibody ELISA. Those that tested positive were expanded and cloned. Secretion levels of the transfectomas were determined by radial immunodiffusion (Table 5). Clones secreting high levels of chimeric antibody were further subcloned. The observed production levels for the anti-P30 and anti-P60 chimeric IgG1 antibodies were 90 μ g/ml or greater. A transfectant secreting anti-P30 chimeric IgM antibody at levels in excess of 100 μ g/ml was obtained by protoplast fusion. Transfection of the anti-P66 chimeric IgM construct has met with more limited success. Transfectomas secreting the chimeric IgM have been obtained, but secretion levels have been rather low (<1 μ g/ml). All of these transfectants have been maintained on 0.1 μ M MTX. Based on previous studies, increasing the MTX concentration may further augment production of the chimeric antibodies (Gillies *et. al.*, J. of Immunol. Methods 125:191-202 (1989); Lo, K.-M. and S. D. Gillies, Biochimica et Biophysica Acta 1088:217-224 (1991)). In three out of four cases, the expression levels of recombinant chimeric antibody produced by the transfectomas actually exceeded the antibody production levels of the hybridomas from which they were derived. Secretion levels required to allow for economical manufacturing have been achieved. Another advantage of the recombinant system is that one can readily generate different classes of antibodies (i.e. IgG1 and IgM) with identical binding specificities.

Table 5 below represents the expression levels of the chimeric antibodies produced using the above procedures:

5

Table 5
Chimeric Antibody Expression Levels

Clone	Specificity	Isotype	Secretion level* (µg/ml)
157-465GS	P30	IgG1	94
243-465GS	P30	IgG1	116
176-706G	P66	IgG1	90
224-465M	P30	IgM	115
223-706M	P66	IgM	0.74

10

*Cells were seeded at a density of 0.5×10^6 . Expression levels were determined at day 7 for the clones or day 14 for subclones (S) by RID assay.

15

v) Assay Performance of the Chimeric Antibodies:

To determine whether the chimeric antibodies had retained their native antigen-binding activity and were capable of functioning as controls/calibrators, they were tested by immunoassay. Protein A-purified chimeric IgG1 antibodies and chimeric IgM fractionated on DEAE were examined for immunoreactivity to *T. gondii* in the Abbott Laboratories IMx Toxo IgG and IgM assays (Safford, J.W. *et. al.*, J. Clin. Pathol. 44:238-242 (1991)). These assays are automated Microparticle Enzyme Immunoassays (MEIA) designed for quantitative (IgG) and qualitative (IgM) measurement of antibodies to *T. gondii* in human serum and plasma.

25

The basic steps of the IMx Toxo IgG assay are depicted in Figure 2. The assay uses microparticles coated with *T. gondii* antigens as the solid phase. Specimen is added to the coated microparticles to allow antibodies specific for *T. gondii* to bind. The microparticles are then transferred onto a glass fiber matrix

and washed extensively to remove any unbound antibody. Subsequently, alkaline phosphatase conjugated goat anti-human IgG antibody is added that binds specifically to IgG class antibodies complexed to the *T. gondii* antigens on the microparticles. Unbound antibody is washed away and the antigen - patient IgG - anti-human IgG conjugate complex is detected by addition of the substrate 4-Methylumbelliferyl Phosphate (MUP). Dephosphorylation of MUP by the alkaline phosphatase can be assessed by the rate of formation of the fluorescent compound Methylumbelliferone (MU) measured on the IMx instrument (Fiore, M. *et. al.*, Clin. Chem. 34:1726-1732 (1988)). This quantitative assay includes a set of 6 calibrators to establish a calibration curve. Calibrators are prepared with human anti-*T. gondii* IgG antibody diluted into human serum at six different concentrations 0, 10, 50, 75, 150, and 300 IU IgG antibody/ml. The calibrators are referenced to the World Health Organization International Standard for anti-*T. gondii* serum. The calibrators are run in place of the specimen and a calibration curve is plotted. Results are interpolated from the six point calibration curve to quantitate IgG levels in the specimens. For this assay, the anti-*T. gondii* IgG positive control is prepared with 20 IU/ml human anti-*T. gondii* IgG diluted into human serum.

The IMx Toxo IgM assay manufactured by Abbott Laboratories is an automated MEIA designed for qualitative measurement of IgM antibodies to *T. gondii*. The assay format is similar to the IMx Toxo IgG assay but the alkaline phosphatase conjugate is goat anti-human IgM antibody. The assay result is expressed as an index value which is the ratio of the specimen counts over the index calibrator. The index calibrator is prepared with human anti-*T. gondii* IgM antibody in human serum and is set near the positive/negative cutoff. The positive control is prepared in the same manner and set to give an index value of 1.5X the index calibrator.

Two-fold serial dilutions of purified anti-P66 chimeric IgG1 antibody at an initial concentration of 11.59 mg/ml and IMx Toxo positive control serum were made in negative human serum (calibrator diluent). The dilutions were run in duplicate and rate counts were determined. The anti-P66 chimeric IgG1 antibody had a flattened curve at concentrations greater than 0.7 mg/ml, reaching a rate count of 2070 at 11.59 mg/ml (Figure 10). The rate count of the 300 IU/ml calibrator (IMx calibrator F) was 2572. Flattening at the top end of the curve seen with the anti-P66 chimeric IgG1 antibody probably reflects saturation of the anti-P66 binding sites in the IMx kit.

To examine the performance of a monoclonal chimeric IgM antibody, purified anti-P66 IgM at 0.210 mg/ml and the IMx Toxo IgM positive control were

diluted serially two-fold in index calibrator diluent. These dilutions were run in duplicate and compared to the positive control and index calibrator (Figure 11). Predicted values for equivalent rate counts to the positive control and index calibrator were read off the dilution curves to determine antibody concentration.

- 5 The index calibrator rate of 710 and positive control rate of 1078 were achieved at 0.0123 mg/ml and 0.0209 mg/ml of chimeric IgM, respectively. These data demonstrate that the monoclonal anti-P66 chimeric IgM functions as an acceptable index calibrator and positive control in this assay. Thus, it appears that the anti-P66 chimeric antibody can substitute for positive human plasma in the manufacture
- 10 of index calibrator and positive control for this assay. In contrast to the anti-P66 chimeric IgG1, the rate counts do not appear to plateau even at the highest concentration tested. This may be due to the structural differences between IgG1 and IgM, as the epitope density would be expected to be roughly equivalent in the two assays. Most IgM is secreted as a pentamer, providing a greater number of
- 15 constant region epitopes, as compared to the dimeric structure of IgG1. Presumably, in the case of the Toxo IgM assay, more of the enzyme-linked secondary antibody (anti-human IgM) binds to the antigen-antibody complex, as compared to the Toxo IgG assay (anti-human IgG), leading to further amplification of the signal.

- 20 Purified anti-P30 chimeric IgG1 antibody at a concentration of 0.87 mg/ml and IMx Toxo positive human serum (calibrator F, 300 IU/ml) were diluted serially two-fold in calibrator diluent to provide antibody levels across the dynamic range (0-300 IU/ml) of the assay. These dilutions were run in duplicate and rate counts (counts/sec/sec) were read off the dilution curves. The chimeric anti-P30
- 25 IgG1 antibody and positive control serum had parallel dilution curves (Figure 12). The 300 IU/ml human serum calibrator (F calibrator) had a rate count of 3015. The anti-P30 chimeric IgG1 reached an equivalent rate count at a concentration of 0.11 mg/ml. No flattening of the curve obtained with the anti-P30 chimeric antibody was observed up to the 4261 rate counts observed at a concentration of
- 30 0.87 mg/ml. Based on these data, the anti-P30 chimeric IgG1 achieved an acceptable signal for an IMx calibration curve. These data demonstrate that one chimeric antibody, specific for a single epitope on P30, has the potential to replace positive human serum used as calibrators and controls in this assay.

- To examine the performance of a chimeric IgM antibody, purified anti-P30
- 35 IgM at 0.104 mg/ml and the IMx Toxo IgM positive control were diluted in index calibrator diluent in two-fold serial dilutions. These dilutions were run in duplicate and compared to the positive control and index calibrator (Figure 13). Predicted values for equivalent rate counts to the positive control and index calibrator were

56

read off these dilution curves and concentrations of antibody determined. The index calibrator rate of 560, and positive control rate of 1050 were achieved at 0.0084 mg/ml and 0.0145 mg/ml of anti-P30 chimeric IgM, respectively. These data demonstrate that an acceptable IMx cutoff value can be obtained with the monoclonal anti-P30 chimeric IgM antibody.

vi) Examination of Accelerated Reagent Stability:

An accelerated stability analysis of the chimeric IgG antibodies in the Toxo IgG assay format was performed by heat-stressing components at 45°C for up to 12 days. For the anti-P30 chimeric IgG1 and a mixture of the two monoclonals (anti-P30 + anti-P66 IgG1), dilutions were run in duplicate against the assay calibration curve in the IMx Toxo IgG assay. A point to point curve fit was used to predict concentrations of chimeric antibodies needed to match the current human antibody calibrators. For the stability analysis, two calibrators levels were examined, the B calibrator of 10 IU/ml and F calibrator of 300 IU/ml. Rate counts equivalent to the B calibrator were achieved with 0.0036 mg/ml of anti-P30 IgG1 or with a mixture of 0.0036 mg/ml anti-P30 and .010 mg/ml anti-P66 IgG1. The kit reagents and calibrators were stored for up to 12 days at 2-8°C or 45°C. On days 0, 4, 8 and 12, assays were run with the test reagents and performance was plotted against the standard human B calibrator (Figure 14). All kit reagents and the chimeric antibodies were stable at 2-8°C. In contrast, when kit reagents were stored at 45°C, by day 4, there was a 30% reduction in rate counts observed for the anti-P30 IgG1 as compared to the standard human B calibrator. By day 12 at 45°C, the signal obtained with the anti-P30 IgG1 was reduced by approximately 50%. The loss of activity was not due to a lack of stability of the chimeric IgG1, as under these conditions, it was as stable as the standard human calibrator antibodies. The reduction in rate counts appears to be due to loss of the P30 epitope recognized by this monoclonal chimeric antibody. When the chimeric antibody mixture was examined, the performance characteristics were similar to that seen for the human antibody calibrator. It would appear the P66 epitope recognized by the monoclonal anti-P66 antibody is more stable under these conditions, and that it compensates for the heat-stress induced loss of the P30 epitope.

To achieve F calibrator levels, 0.110 mg/ml of anti-P30 IgG1 or a mixture of 0.110 anti-P30 and 0.305 mg/ml anti-P66 IgG1 were used. Assay performance with the test reagents relative to that seen with the standard human calibrator is shown in Figure 15. All kit reagents and the chimeric antibodies were stable when stored at 2-8°C. Similar to the results observed at the B calibrator

level, there was a progressive decline in rate counts observed with the anti-P30 antibody when stored at 45°C. The combination of the anti-P30 and anti-P66 monoclonals, exhibited acceptable stability characteristics as compared to the native human F calibrator even after heat-stress at 45°C. The loss of stability with the anti-P30 chimeric antibody appears to be due to loss of the P30 epitope recognized by this monoclonal, as the chimeric anti-P30 antibody showed no difference in stability relative to the human calibrator antibodies.

These data demonstrate that chimeric antibodies can be produced that have stability characteristics suitable for commercial manufacturing. The slow decay seen with heat-stress of the P30 epitope highlights the importance of carefully choosing the epitope recognized by the chimeric antibody. In this case, a comparison was made between the binding characteristics of a monoclonal chimeric antibody and those of a polyclonal antiserum. In the latter case, multiple epitopes on a given antigen (e.g. P30) are being recognized, and the loss of any single one may not be discernible. An advantage of this technology is that one can screen candidate murine monoclonal antibodies for desired properties prior to cloning of the V regions and producing the chimeric antibody. The properties of the chimeric antibody will reflect those of the original donor antibody. For the IMx Toxo IgG assay, by blending the anti-P30 and anti-P66 chimeric antibodies, the combined characteristics provide a performance level equivalent to the standard human antibody calibrators. This establishes that chimeric antibodies can be utilized as controls and calibrators in place of positive human serum. In some cases, a single monoclonal chimeric antibody may suffice. In other cases, it may be necessary to pool more than one chimeric antibody to reach desired assay performance characteristics.

vii) Analysis of Lot-to-Lot Antigen Variation:

To examine whether there was significant lot-to-lot variation in the expression of the P30 and P66 epitopes recognized by the chimeric antibodies, mixtures of the anti-P30 and anti-P66 chimeric antibodies at the B calibrator and F calibrator levels were tested with multiple lots of antigens. The results of this analysis with seven independent lots of antigens is shown in Figure 16. Performance of both mixtures of anti-P66 and anti-P30 chimeric antibodies were

comparable (within assay variability) to the current IMx human serum calibrator. This further validates the potential of mouse-human chimeric antibodies as a substitute for positive human antibodies.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Hackett, Jr., John R.
Hoff, Jane A.
Ostrow, David H.
Golden, Alan M.
- (ii) TITLE OF INVENTION: REAGENTS FOR USE AS CALIBRATORS AND CONTROLS
- (iii) NUMBER OF SEQUENCES: 70
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Abbott Laboratories
 - (B) STREET: 100 Abbott Park Road
 - (C) CITY: Abbott Park
 - (D) STATE: IL
 - (E) COUNTRY: US
 - (F) ZIP: 60064-3500
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Becker, Cheryl L.
 - (B) REGISTRATION NUMBER: 35,441
 - (C) REFERENCE/DOCKET NUMBER: 5865.US.01
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 847-935-1729
 - (B) TELEFAX: 847-938-2623

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 138 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Val Thr Ala Gly
 1 5 10 15

Val His Ser Gln Val His Leu Gln Gln Ser Gly Ala Glu Leu Val Arg
 20 25 30

Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe
 35 40 45

Thr Asn Tyr Leu Ile Glu Trp Val Thr Gln Arg Pro Gly Gln Gly Leu
 50 55 60

Glu Trp Ile Gly Val Ile Asn Pro Gly Ser Asp Phe Thr Tyr Tyr Asn
 65 70 75 80

Glu Lys Phe Lys Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95

Thr Ala Tyr Met Gln Leu Thr Ser Leu Thr Ser Asp Asp Ser Ala Val
 100 105 110

Tyr Phe Cys Ala Arg Thr Ile Val Thr Thr Asp Tyr Phe Asp Tyr Trp
 115 120 125

Gly Gln Gly Thr Pro Leu Thr Val Ser Ser
 130 135

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTCGAGACTC CAACCATGGG ATGGAGCTGG ATCTTTCTCT TTCTCCTGTC AGTAACTGCA 60

GGTGTTCACT CCCAGGTCCA TCTGCAGCAG TCTGGAGCTG AGCTGGTAAG GCCTGGGACT 120

TCAGTGAAGG TGTCTTGCAA GGCTTCTGGA TACGCCTTCA CTAATTACTT GATAGAGTGG 180

GTGACACAGA GGCCTGGACA GGGCCTTGAG TGGATTGGAG TGATTAATCC TGGAAGTGAT 240

TTTACTTACT ACAATGAGAA ATTCAAGGGC AGGGCAACAC TGACTGCAGA CAAATCCTCC 300

AGCACTGCCT ACATGCAGCT CACCAGCCTG ACATCTGATG ACTCTGCGGT CTATTTCTGT 360

GCAAGAACTA TTGTGACTAC GGACTACTTT GACTACTGGG GCCAAGGCAC CCCTCTCACA 420

61

GTCTCCTCAG GTAAGTGTGT CAAGCTT

447

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 131 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Glu Ser Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1             5             10             15
Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala
 20             25             30
Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser
 35             40             45
Val Ser Ile Arg Gly Ala Gly Leu Met His Trp Tyr Gln Gln Lys Pro
 50             55             60
Gly Tyr Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser
 65             70             75             80
Gly Val Pro Ala Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr
 85             90             95
Leu Asn Ile His Pro Val Glu Glu Ala Asp Ala Ala Thr Tyr Phe Cys
 100            105            110
Gln Gln Ser Arg Arg Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu
 115            120            125
Glu Ile Lys
 130

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 428 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCTAGAGCTC TCAGAGATGG AGTCAGACAC ACTCCTGCTA TGGGTGCTAC TGCTCTGGGT	60
TCCAGGCTCC ACTGGTGACA TTGTGCTGAC CCAATCTCCA GCTTCTTTGG CTGTGTCTCT	120
GGGGCAGAGG GCCACCATCT CCTGCAGAGC CAGCGAAAAGT GTCAGTATTC GTGGTGCTGG	180
TTTAATGCAC TGGTATCAAC AGAAACCAGG ATATCCACCC AAATCCTCA TCTATGCTGC	240
ATCCAACCTA GAATCTGGGG TGCCTGCCAG GTTTAGTGGC AGAGGGTCTG GGACAGACTT	300
CACCCCTCAAC ATTCATCCTG TGGAGGAAGC TGATGCTGCA ACCTATTTCT GTCAGCAAAG	360
TAGGAGATAT CCGTATACGT TCGGATCGGG GACCAAGCTG GAAATAAAAC GTAAGTGTGT	420
CAGGATCC	428

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 141 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met	Ala	Trp	Val	Trp	Thr	Leu	Leu	Phe	Leu	Met	Ala	Ala	Ala	Gln	Ser	1	5	10	15
Ile	Gln	Ala	Gln	Ile	Gln	Leu	Val	Gln	Ser	Gly	Pro	Glu	Leu	Lys	Lys	20	25	30	
Pro	Gly	Glu	Thr	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	35	40	45	
Thr	His	Tyr	Pro	Met	His	Trp	Val	Lys	Gln	Ala	Pro	Gly	Lys	Ser	Leu	50	55	60	
Lys	Trp	Met	Gly	Trp	Ile	Asn	Thr	Lys	Ser	Gly	Val	Pro	Thr	Tyr	Ala	65	70	75	80
Asp	Asp	Phe	Lys	Gly	Arg	Phe	Ala	Phe	Ser	Leu	Glu	Thr	Ser	Ala	Ser	85	90	95	
Thr	Ala	Cys	Leu	Gln	Ile	Thr	Asn	Leu	Lys	Asn	Glu	Asp	Met	Ala	Thr	100	105	110	
Tyr	Phe	Cys	Val	Arg	Gly	Gly	Leu	Tyr	Tyr	Asp	Tyr	Phe	Tyr	Gly	Val	115	120	125	

63

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 130 135 140

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 452 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

CTCGAGACAT CATGGCTTGG GTGTGGACCT TGCTATTCCT GATGGCAGCT GCCCAAAGTA      60
TCCAAGCACA GATCCAGTTG GTGCAGTCTG GACCTGAGCT GAAGAAGCCT GGAGAGACAG      120
TCAAGATCTC CTGCAAGGCT TCTGGGTATA CCTTCACACA CTATCCAATG CACTGGGTGA      180
AGCAGGCTCC AGGAAAGAGT TTAAAGTGA TGGGCTGGAT AAACACCAAG TCTGGAGTGC      240
CAACATATGC AGATGACTTC AAGGGACGGT TTGCCTTCTC TTTGGAAACC TCTGCCAGCA      300
CTGCATGTTT GCAGATCACC AACCTCAAAA ATGAGGACAT GGCTACATAT TTCTGTGTAA      360
GAGGAGGGCT CTACTATGAT TATTTCTATG GTGTGGACTA CTGGGGTCAA GGAACCTCAG      420
TCACCGTCTC CTCAGGTAAG TGTGTCAAGC TT                                     452

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 131 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
1           5           10           15
Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val
20           25           30
Ser Pro Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
35           40           45

```

64

Val His Ser Tyr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro
 50 55 60

Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
 65 70 75 80

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 85 90 95

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys
 100 105 110

Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu
 115 120 125

Glu Ile Lys
 130

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 424 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TCTAGACCTC AAATGAAGTT GCCTGTTAGG CTGTTGGTGC TGATGTTCTG GATTCCTGCT 60

TCCAGCAGTG ATGTGGTGAT GACCCAGACT CCACTCTCCC TGCCTGTCAG TCCTGGAGAT 120

CAAGCCTCGA TCTCTTGCAG ATCTAGTCAG AGCCTTGTAC ACAGTTATGG AAACACCTAT 180

TTACATTGGT ATCTGCAGAA GCCAGGCCAG TCTCCAAAC TCCTGATCTA CAAAGTTTCC 240

AACCGATTTT CTGGGGTCCC AGACAGGTTT AGTGGCAGTG GATCAGGGAC AGATTTTACA 300

CTCAAGATCA GCAGAGTGGA GGCTGAGGAT CTGGGAGTTT ATTTCTGCTC TCAAAGTACA 360

CATGTTCCGT GGACGTTCCG TGGAGGCACC AAGCTGGAAA TCAAACGTAA GTGTGTCAGG 420

ATCC 424

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

65

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATTCGGATAG ATCTAGTGGA TAGACTGATG G

31

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATTCGGATAG ATCTAGTGGA TAGACCGATG G

31

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATTCGGATAG ATCTTGGATG GTGGGAAGAT G

31

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

66

ACACTAGTCG ACATGGMTTG GGTGTGGAMC TTGCTATTCC TG

42

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ACACTAGTCG ACATGAAGTT GCCTGTTAGG CTGTTGGTGC TG

42

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACACTAGTCG ACATGGGRATG GAGCKGGRTC TTTMTCTT

38

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ACACTAGTCG ACATGGAGWC AGACACACTC CTGYTATGGG T

41

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 61 base pairs

67

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGACTGTAAAC TAGTCCTGCG GGTCTCAGG GAGTGCATCC GCCCCAACCC TTTTCCCCCT
C

60

61

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGACGGGGAA TTCTCACAGG AGAC

24

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGAAGTAGTG GAGC

14

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

68

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCCACTAGTT CCGC

14

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ACGTCATCCG ACCCCCTCAG

20

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTGCCCCAAA GCCAAGGTCA

20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

69

CTCCAGCTTC ACCAGATCCC TCGAC

25

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CTCCAGCTTC ACCAGATCCC TCGAG

25

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GCCACCTGCC TCACCTTAG

19

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AGAATGGCCA CGTCATCCG

19

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs

70

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TCCAATGCAC TGGGTGAAGC

20

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GCAAACCGTC CCTTGAAGTC

20

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATTTACATTG GTATCTGCAG

20

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

71

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CCAGAAAATC GGTTGGAAC

20

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CGAGACTCCA ACCATGGGAT

20

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TGATAGAGTG GGTGACACAG

20

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GCCCTGCCCT TGAATTTCTC

20

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TAGAGCTCTC AGAGATGGAG

20

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CTATGCTGCA TCCAACCTAG

20

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GATGAATGTT GAGGGTGAAG

20

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

73

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ATACAAGAAC AACTCTGACA

20

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GTCTTCGTCC CACCCCGCG

19

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CTCCATGTGT GTCCCCGGTG

20

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

74

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ATCCTTTGCC AGCATCTTCC

20

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

ACTCTTGCCC CTCTTCCTGC

20

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GACCAGCGCC CCAATGCCTG

20

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

TTTGCATGCA CACACAGAGC

20

(2) INFORMATION FOR SEQ ID NO:43:

75

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GCATCCACTG CACGAAGACG

20

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

AGGGCAGGTC TGTGTGGGTC

20

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

CATGGTTCCC ACCCAAAGAG

20

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

76

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

ACTCTTTGGC CTCAGCCTGC

20

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GCACACCACG TGTCGTCTG

20

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GTGCATGCAA ACTAACCGTG

20

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

77

GCTCCTCCCA TATGGTCGAC

20

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CAGGCCCGAT GTCTACTTGC

20

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

CTCATGGGCC ACCACGCAGG

20

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

CTGCGAGGAT GACTGGAATT

20

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

78

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GCTGGTCACA TACTTCTCCG

20

(2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

CGGGAGCTGC ATGTGTCAG

19

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

CAGACACTGG ACGCTGAACC

20

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TGATCTAGCG GCCGTCGCAC TCAGTAGCAG GTGCCAGCTG TGTCGGAC

48

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

CTGATCGAGA TATCAAGCCA CTGAGGCACG CAGGTGGGTG

40

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TCAGGTGACT GAACTAGTCC TTGGTGGGGC AGCCACAGCG

40

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

TCACGAAGTC TAGACCTCAA ATGAAGTTGC CTGTTAGGCT GTTGGTG

47

80

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GAATCTATGG ATCCTGACAC ACTTACGTTT GATTTCACGC TTGGTGCCTC C

51

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

ACACTATACT CGAGACATCA TGGCTTGGGT GTGGACCTTG CTA

43

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

TTCAGATCAA GCTTGACACA CTTACCTGAG GAGACGGTGA CTGAGGTTCC

50

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

81

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

TCACGAAGTC TAGAGCTCTC AGAGATGGAG TCAGACACAC TCCTGCTA

48

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GAATCTATGG ATCCTGACAC ACTTACGTTT TATTTCCAGC TTGGTCCCCG

50

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

ACACTATACT CGAGACTCCA ACCATGGGAT GGAGCTGGAT CTTTCTC

47

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

82

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

TTCAGATCAA GCTTGACACA CTTACCTGAG GAGACTGTGA GAGGGGTG

48

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

GTAAAACGAC GGCCAGT

17

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

CAGGAAACAG CTATGAC

17

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

GAGCGGATAA CAATTCACA CAGG

24

(2) INFORMATION FOR SEQ ID NO:70:

83

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

TGTAACACGA CGGCCAGT

18

CLAIMS:

1. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample
5 suspected of containing said antibody with antigen specific for said antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) detecting the presence of said antibody which may be present in said test sample, and (c) employing, as a control or calibrator, a reagent which binds to said antigen, wherein the improvement comprises employing, as said control or calibrator, a reagent
10 comprising one or more antibody constant region epitopes, wherein said reagent binds to said antigen and is homogeneous with respect to specificity and affinity.

2. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample
15 suspected of containing said antibody with antigen specific for said antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) detecting the presence of said antibody which may be present in said test sample, and (c) employing, as a control or calibrator, two or more reagents which bind to said antigen, wherein the improvement comprises employing, as said control or calibrator,
20 two or more reagents each comprising one or more antibody constant region epitopes, wherein each of said two or more reagents binds to different epitopes on said antigen and is homogeneous with respect to specificity and affinity.

3. In a method for detecting the presence of antibody which may be present
25 in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with antigen specific for said antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) adding a direct or indirect conjugate to said resulting antigen/antibody complexes for a time and under conditions sufficient to allow said conjugate to bind to said bound
30 antibody, wherein said conjugate comprises an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of said antibody which may be present in said test sample by detecting the signal generated by said signal generating compound, and (d) employing, as a control or calibrator, a reagent which binds to said antigen, wherein the improvement comprises employing, as
35 said control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein said reagent binds to said antigen and is homogeneous with respect to specificity and affinity.

85

4. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with antigen specific for said antibody for a time and under conditions sufficient to allow the formation of antigen/antibody complexes,
- 5 (b) adding a direct or indirect conjugate to said resulting antigen/antibody complexes for a time and under conditions sufficient to allow said conjugate to bind to said bound antibody, wherein said conjugate comprises an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of said antibody which may be present in said test sample by detecting the signal generated by
- 10 said signal generating compound, and (d) employing, as a control or calibrator, two or more reagents which bind to said antigen, wherein the improvement comprises employing, as said control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of said two or more reagents binds to different epitopes on said antigen and is homogeneous with respect to
- 15 specificity and affinity.

5. A kit for determining the presence of antibody in a test sample comprising:

- a) an antigen specific for said antibody; and
- 20 b) a control or calibrator comprising a reagent wherein said reagent comprises one or more antibody constant region epitopes, binds to said antigen, and is homogeneous with respect to specificity and affinity.

6. A kit for determining the presence of antibody in a test sample comprising:

- a) an antigen specific for said antibody; and
- 25 b) a control or calibrator comprising two or more reagents wherein each of said two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and
- 30 affinity.

7. A kit for determining the presence of antibody in a test sample comprising:

- a) an antigen specific for said antibody;
- 35 b) a direct or indirect conjugate comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and

86

c) a control or calibrator comprising a reagent wherein said reagent comprises one or more antibody constant region epitopes, binds to said antigen, and is homogeneous with respect to specificity and affinity.

5 8. A kit for determining the presence of antibody in a test sample comprising:

a) an antigen specific for said antibody;

b) a direct or indirect conjugate comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and

10 c) a control or calibrator comprising two or more reagents wherein each of said two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.

15 9. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with anti-antibody specific for said antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) detecting the presence of said antibody which may be present in said
20 test sample, and (c) employing, as a control or calibrator, a reagent which binds to said anti-antibody, wherein the improvement comprises employing, as said control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein said reagent binds to said antigen and is homogeneous with respect to specificity and affinity.

25

10. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with anti-antibody specific for said antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody
30 complexes, (b) detecting the presence of said antibody which may be present in said test sample, and (c) employing, as a control or calibrator, two or more reagents which bind to said anti-antibody, wherein the improvement comprises employing, as said control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of said two or more reagents binds to different
35 epitopes on said antigen and is homogeneous with respect to specificity and affinity.

87

11. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with anti-antibody specific for said antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) adding a conjugate to said resulting anti-antibody/antibody complexes for a time and under conditions sufficient to allow said conjugate to bind to said bound antibody, wherein said conjugate comprises an antigen attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of said antibody which may be present in said test sample by detecting the signal generated by said signal generating compound, and (d) employing, as a control or calibrator, a reagent which comprises antibody to said anti-antibody, wherein the improvement comprises employing, as said control or calibrator, a reagent comprising one or more antibody constant region epitopes, wherein said reagent binds to said antigen and is homogeneous with respect to specificity and affinity.

12. In a method for detecting the presence of antibody which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibody with anti-antibody specific for said antibody for a time and under conditions sufficient to allow the formation of anti-antibody/antibody complexes, (b) adding a conjugate to said resulting anti-antibody/antibody complexes for a time and under conditions sufficient to allow said conjugate to bind to said bound antibody, wherein said conjugate comprises an antigen attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of said antibody which may be present in said test sample by detecting the signal generated by said signal generating compound, and (d) employing, as a control or calibrator, two or more reagents which bind to said anti-antibody, wherein the improvement comprises employing, as said control or calibrator, two or more reagents each comprising one or more antibody constant region epitopes, wherein each of said two or more reagents binds to different epitopes on said antigen and has a unique specificity and affinity.

13. A kit for determining the presence of antibody in a test sample comprising:

- a) an anti-antibody specific for said antibody;
- b) an antigen specific for said antibody; and
- c) a control or calibrator comprising a reagent wherein said reagent comprises one or more antibody constant region epitopes, binds to said antigen, and is homogeneous with respect to specificity and affinity.

14. A kit for determining the presence of antibody in a test sample comprising:

- a) an anti-antibody specific for said antibody;
- b) an antigen specific for said antibody; and
- 5 c) a control or calibrator comprising two or more reagents wherein each of said two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.

10 15. A kit for determining the presence of antibody in a test sample comprising:

- a) an anti-antibody specific for said antibody;
- b) a direct or indirect conjugate comprising an antigen attached to a signal generating compound capable of generating a detectable signal; and
- 15 c) a control or calibrator comprising a reagent wherein said reagent comprises one or more antibody constant region epitopes, binds to said antigen, and is homogeneous with respect to specificity and affinity.

20 16. A kit for determining the presence of antibody in a test sample comprising:

- a) an anti-antibody specific for said antibody;
- b) a direct or indirect conjugate comprising an antigen attached to a signal generating compound capable of generating a detectable signal; and
- 25 c) a control or calibrator comprising two or more reagents wherein each of said two or more reagents comprises one or more antibody constant region epitopes, binds to different epitopes on said antigen, and is homogeneous with respect to specificity and affinity.


30 17. In a method for detecting the presence of antibodies, developed against more than one antigen, which may be present in a test sample wherein said method comprises (a) contacting said test sample suspected of containing said antibodies with antigens specific for said antibodies, respectively, for a time and under conditions sufficient to allow the formation of antigen/antibody complexes, (b) adding direct or indirect conjugates to said antigen/antibody complexes for a time and under conditions
35 sufficient to allow said conjugates to bind to said bound antibodies, wherein said conjugates comprise an antibody attached to a signal generating compound capable of generating a detectable signal, (c) detecting the presence of said antibodies which may be present in said test sample by detecting the signal generated by said signal generating

89

compound, and (d) employing, as controls or calibrators, reagents which bind to said antigens, wherein the improvement comprises employing, as said controls or calibrators, reagents, each comprising one or more antibody constant region epitopes, wherein each of said reagents bind to said antigens, respectively, and is homogeneous
5 with respect to specificity and affinity.

18. A kit for determining the presence of antibodies, developed against more than one antigen, which may be present in a test sample, comprising:

- a) antigens specific for said antibodies, respectively;
- 10 b) direct or indirect conjugates each comprising an antibody attached to a signal generating compound capable of generating a detectable signal; and
- c) controls or calibrators comprising reagents wherein each of said reagents comprises one or more antibody constant region epitopes, bind to said respective
15 antigens, and is homogeneous with respect to specificity and affinity.

Figure 1

Murine Regions



Human Regions

Figure 2





Figure 3

pdHL2 (9193 bp)



pJH2-24-95B1 (9770 bp)




Figure 4





Figure 5



6/16

Figure 6

Xho I
CTCGAGACTC CAACCATGGG ATGGAGCTGG ATCTTTCTCT TTCTCCTGTC 50
M G W S W I F L F L L S

AGTAACTGCA GGTGTTCACT CCCAGGTCCA TCTGCAGCAG TCTGGAGCTG 100
V T A G V H S -Q V H L Q Q S G A E
+1

AGCTGGTAAG GCCTGGGACT TCAGTGAAGG TGTCCTGCAA GGCTTCTGGA 150
L V R P G T S V K V S C K A S G

CDR1
TACGCCTTCA CTAATTACTT GATAGAGTGG GTGACACAGA GGCCTGGACA 200
Y A F T N Y L I E W V T Q R P G Q

CDR2
GGCCTTGAG TGGATTGGAG TGATTAATCC TGGAAGTGAT TTTACTTACT 250
G L E W I G V I N P G S D F T Y Y

ACAATGAGAA ATTCAAGGGC AGGGCAACAC TGACTGCAGA CAAATCCTCC 300
N E K F K G R A T L T A D K S S

AGCACTGCCT ACATGCAGCT CACCAGCCTG ACATCTGATG ACTCTGCGGT 350
S T A Y M Q L T S L T S D D S A V

CDR3
CTATTTCTGT GCAAGAACTA TTGTGACTAC GGACTACTTT GACTACTGGG 400
Y F C A R T I V T T D Y F D Y W G

GCCAAGGCAC CCCTCTCACA GTCTCCTCAG CTAAGCTT 447
Q G T P L T V S S
Hind III

7/16

Figure 7

Xba I
TCTAGAGCTC TCAGAGATGG AGTCAGACAC ACTCCTGCTA TGGGTGCTAC 50
 M E S D T L L L W V L L

TGCTCTGGGT TCCAGGCTCC ACTGGTGACA TTGTGCTGAC CCAATCTCCA 100
 L W V P G S T G D I V L T Q S P
 +1

GCTTCTTTGG CTGTGTCTCT GGGGCAGAGG GCCACCATCT CCTGCAGAGC 150
 A S L A V S L G Q R A T I S C R A

 CDR1
 CAGCGAAAGT GTCAGTATTC GTGGTGCTGG TTTAATGCAC TGGTATCAAC 200
 S E S V S I R G A G L M H W Y Q Q

 CDR2
 AGAAACCAGG ATATCCACCC AAATCCTCA TCTATGCTGC ATCCAACCTA 250
 K P G Y P P K L L I Y A A S N L

GAATCTGGGG TGCCTGCCAG GTTTAGTGGC AGAGGGTCTG GGACAGACTT 300
 E S G V P A R F S G R G S G T D F

CACCCTCAAC ATTCATCCTG TGGAGGAAGC TGATGCTGCA ACCTATTTCT 350
 T L N I H P V E E A D A A T Y F C

 CDR3
 GTCAGCAAAG TAGGAGATAT CCGTATACGT TCGGATCGGG GACCAAGCTG 400
 Q Q S R R Y P Y T F G S G T K L

 ↓
 GAAATAAAAC GTAAGTGTGT CAGGATCC 428
 E I K Bam HI

Figure 8

Xho I

CTCGAGACAT CATGGCTTGG GTGTGGACCT TGCTATTCCT GATGGCAGCT 50
M A W V W T L L F L M A A

GCCCAAAGTA TCCAAGCACA GATCCAGTTG GTGCAGTCTG GACCTGAGCT 100
A Q S I Q A Q I Q L V Q S G P E L
+1

GAAGAAGCCT GGAGAGACAG TCAAGATCTC CTGCAAGGCT TCTGGGTATA 150
K K P G E T V K I S C K A S G Y T

CDR1
CCTTCACACA CTATCCAATG CACTGGGTGA AGCAGGCTCC AGGAAAGAGT 200
F T H Y P M H W V K Q A P G K S

CDR2
TTAAAGTGGA TGGGCTGGAT AAACACCAAG TCTGGAGTGC CAACATATGC 250
L K W M G W I N T K S G V P T Y A

AGATGACTTC AAGGGACGGT TTGCCTTCTC TTTGGAAACC TCTGCCAGCA 300
D D F K G R F A F S L E T S A S T

CTGCATGTTT GCAGATCACC AACCTCAAAA ATGAGGACAT GGCTACATAT 350
A C L Q I T N L K N E D M A T Y

CDR3
TTCTGTGTAA GAGGAGGGCT CTA CTATGAT TATTTCTATG GTGTGGACTA 400
F C V R G G L Y Y D Y F Y G V D Y

CTGGGGTCAA GGAACCTCAG TCACCGTCTC CTCAGGTAAG TGTGTCAAGCTT 452
W G Q G T S V T V S S Hind III

9/16

Figure 9

Xba I

TCTAGACCTC AAATGAAGTT GCCTGTTAGG CTGTTGGTGC TGATGTTCTG 50
M K L P V R L L V L M F W

GATTCCTGCT TCCAGCAGTG ATGTGGTGAT GACCCAGACT CCACTCTCCC 100
I P A S S S D -V V M T Q T P L S L
+1

TGCCTGTCAG TCCTGGAGAT CAAGCCTCGA TCTCTTGCAG ATCTAGTCAG 150
P V S P G D Q A S I S C R S S Q

CDR1
AGCCTTGTAC ACAGTTATGG AAACACCTAT TTACATTGGT ATCTGCAGAA 200
S L V H S Y G N T Y L H W Y L Q K

CDR2
GCCAGGCCAG TCTCCAAAAC TCCTGATCTA CAAAGTTTCC AACCGATTTT 250
P G Q S P K L L I Y K V S N R F S

CTGGGGTCCC AGACAGGTTC AGTGGCAGTG GATCAGGGAC AGATTTCACA 300
G V P D R F S G S G S G T D F T


CTCAAGATCA GCAGAGTGGA GGCTGAGGAT CTGGGAGTTT ATTTCTGCTC 350
L K I S R V E A E D L G V Y F C S

CDR3
TCAAAGTACA CATGTTCCGT GGACGTTCCG TGGAGGCACC AAGCTGGAAA 400
Q S T H V P W T F G G G T K L E I

↓
TCAAACGTAA GTGTGTCA**GG ATCC** 424
K Bam HI


10/16

Figure 10



11/16

Figure 11



12/16

Figure 12




Figure 13






Figure 14
Chimeric Anti-P30/ Anti-P66 vs Current Cals vs 45 deg C Stability



16/16

Figure 16
Chimeric Anti-P30/ Anti-P66 IgG Mix vs
Current Cals vs Ag Lot



INTERNATIONAL SEARCH REPORT

International Application No

PL/US 97/01074

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/96 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 062 227 A (BEHRINGWERKE AG) 13 October 1982 ---	
A	EP 0 537 488 A (BEHRINGWERKE AG) 21 April 1993 ---	
A	EP 0 429 218 A (BAXTER INT) 29 May 1991 ---	
A	WO 91 19196 A (NOVONORDISK AS) 12 December 1991 ---	
A	EP 0 636 886 A (PB DIAGNOSTIC SYSTEMS INC) 1 February 1995 cited in the application & US 5 478 753 A ---	
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "&" document member of the same patent family

Date of the actual completion of the international search

3 June 1997

Date of mailing of the international search report

10.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Cartagena y Abella, P

INTERNATIONAL SEARCH REPORT

International Application No

PL./US 97/01074

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 89 10980 A (BIO RES LAB INC) 16 November 1989 cited in the application & US 5 008 183 A</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL./US 97/01074

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0062227 A	13-10-82	DE 3112334 A JP 57171264 A	07-10-82 21-10-82
EP 0537488 A	21-04-93	DE 4133945 A AU 670042 B AU 2637492 A CA 2080408 A JP 5232111 A NZ 244681 A US 5491218 A ZA 9207861 A	15-04-93 04-07-96 22-04-93 15-04-93 07-09-93 22-12-94 13-02-96 27-04-93
EP 0429218 A	29-05-91	NONE	
WO 9119196 A	12-12-91	AU 7967891 A CS 9101735 A EP 0532627 A US 5387503 A	31-12-91 19-02-92 24-03-93 07-02-95
EP 0636886 A	01-02-95	US 5478753 A	26-12-95
WO 8910980 A	16-11-89	US 5008183 A AT 123072 T AU 3689389 A CA 1338412 A DE 68922842 D DE 68922842 T EP 0383851 A US 5264342 A	16-04-91 15-06-95 29-11-89 18-06-96 29-06-95 21-09-95 29-08-90 23-11-93

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the transparency and accountability of the organization. The document then outlines the specific procedures for recording transactions, including the use of standardized forms and the requirement for double-entry bookkeeping. It also addresses the need for regular audits to ensure the integrity of the financial data.

The second part of the document focuses on the management of the organization's assets. It provides a detailed overview of the inventory control system, which includes the use of barcodes and the implementation of a first-in, first-out (FIFO) policy. The document also discusses the importance of regular physical counts to reconcile the physical inventory with the recorded inventory. Additionally, it outlines the procedures for the disposal of obsolete or damaged assets, ensuring that all disposals are properly documented and approved.

The third part of the document deals with the organization's human resources. It outlines the recruitment process, which involves the use of job descriptions and the establishment of a selection committee. The document also discusses the importance of employee training and development, highlighting the need for ongoing education and skill enhancement. Furthermore, it addresses the issue of employee compensation, emphasizing the need for a fair and competitive salary structure that is based on market research and internal equity.

The final part of the document provides a summary of the key findings and recommendations. It reiterates the importance of maintaining accurate records, managing assets effectively, and ensuring the well-being of the organization's human resources. The document concludes by stating that these measures are essential for the long-term success and sustainability of the organization.